[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 310
1. Takahashi T, Ohashi E, Nakagawa T, Mochizuki M, Nishimura R, Sasaki N: Role of beta1 integrins in adhesion of canine mastocytoma cells to extracellular matrix proteins. J Vet Med Sci; 2007 May;69(5):495-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of beta1 integrins in adhesion of canine mastocytoma cells to extracellular matrix proteins.
  • The interactions of tumor cells with the extracellular matrix (ECM) are a crucial step in invasion and metastasis.
  • In this study, mastocytoma (mast cell tumor: MCT) cell-ECM interaction was investigated using 3 canine MCT cell lines: CM-MC (originating from cutaneous MCT), VI-MC (originating from intestinal MCT), and CoMS (originating from oral MCT).
  • Flow cytometric analysis showed that all cells highly expressed the integrin beta1 and alpha1 through alpha5 subunits and that they moderately expressed the alpha6 subunit.
  • In adhesion studies, CoMS weakly but spontaneously adhered to fibronectin (FN), which was enhanced by phorbol ester (TPA), while CM-MC and VI-MC required cell activation by TPA to adhere to FN.
  • Anti-beta1 and alpha5 integrin antibodies strongly inhibited cell adhesion to FN in CM-MC and CoMS and moderately inhibited cell adhesion in VI-MC.
  • Anti-beta1 integrin antibodies strongly inhibited cell adhesion to LN, but all anti-alpha integrin antibodies failed to inhibit cell adhesion to LN.
  • No cells adhered to collagen types I and IV.
  • Canine MCT cells from different origins expressed similar integrin patterns; however, there were some differences in adhesive behavior in response to various ECM proteins and activating stimuli.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551222.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Extracellular Matrix Proteins; 0 / Integrin beta Chains
  •  go-up   go-down


2. Riva F, Brizzola S, Stefanello D, Crema S, Turin L: A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest; 2005 Jul;17(4):385-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of mutations in the c-kit gene of 32 dogs with mastocytoma.
  • Mutations in the intracellular juxtamembrane domain of the c-kit gene in 32 dogs with different grades of histologically confirmed mastocytoma were studied.
  • The region corresponding to the c-kit juxtamembrane domain was sequenced and compared with GenBank sequences.
  • The c-kit juxtamembrane domain sequences of all dogs were grouped in 3 clusters.
  • No mutations were detected in tissues constitutively expressing c-kit (cerebellum and spleen), obtained from dogs not affected by mastocytoma (controls).
  • All the substitutions were found in dogs bearing grade I or II mast cell tumors; the deletion was detected in 1 dog with grade II mastocytoma.
  • [MeSH-major] Dog Diseases / genetics. Mastocytoma / veterinary. Mutation. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Animals. Base Sequence. Dogs. Female. Male. Molecular Sequence Data. Oncogenes. Polymerase Chain Reaction / veterinary. RNA, Neoplasm / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131001.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


3. Pandhi D, Singal A, Aggarwal S: Adult onset, hypopigmented solitary mastocytoma: report of two cases. Indian J Dermatol Venereol Leprol; 2008 Jan-Feb;74(1):41-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult onset, hypopigmented solitary mastocytoma: report of two cases.
  • Solitary mastocytoma is known to occur predominantly in children below 2 years of age and onset in adulthood is rare.
  • Lesions are hyperpigmented in the majority of cases owing to the stimulation of melanin synthesis by mast cell growth factor.
  • We hereby report two patients with adult onset solitary mastocytoma presenting as hypopigmented plaque.
  • Histopathology revealed a dense toluidine blue-positive infiltrate of mast cells in the upper dermis in both cases.
  • [MeSH-major] Hypopigmentation / pathology. Mastocytoma, Skin / pathology
  • [MeSH-minor] Adult. Age of Onset. Biopsy. Dermis / pathology. Eosinophils / pathology. Humans. Male. Mast Cells / pathology. Neck

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187823.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Turin L, Acocella F, Stefanello D, Oseliero A, Fondrini D, Brizzola S, Riva F: Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction. J Vet Diagn Invest; 2006 Jul;18(4):343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction.
  • KIT receptor, the c-kit gene product, is thought to play a major role in canine mastocytoma, one of the most common neoplastic diseases in dogs.
  • In the present study, the expression of c-kit proto-oncogene in blood and in tumor biopsies from 41 dogs with histologically confirmed mastocytoma at different grades of cellular differentiation and 5 negative control dogs was investigated using real-time (quantitative) reverse transcription-polymerase chain reaction (RRT-PCR).
  • The animals were followed up for over 1 year after surgery in order to characterize the kinetics of c-kit expression in blood.
  • Transcript mRNAs extracted from blood at different time points after surgery and from tumor tissue surgically removed from each dog were used in a quantitative RRT-PCR assay targeting the extracellular coding region of the c-kit gene.
  • Levels of expression of c-kit were higher in tumor biopsies than in blood; the blood level decreased in the patients between 1 and 3 months after surgery.
  • No KIT expression was detected in blood from the 5 dogs not affected by mastocytoma (negative controls).
  • The RRT-PCR appears to be a suitable method for sensitive and quantitative detection of c-kit gene expression in canine blood and neoplastic tissues.
  • Although c-kit expression levels measured by RRT-PCR do not correlate with prognosis, they confirm that surgery remains the main treatment to reduce circulating mastocytes and that circulating mast cells can be detected even in benign highly differentiated forms of mastocytoma such as grade I.
  • [MeSH-major] Dog Diseases / genetics. Gene Expression Regulation, Neoplastic. Mastocytoma / veterinary. Polymerase Chain Reaction / veterinary. Proto-Oncogene Proteins c-kit / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921872.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


5. Furuta K, Nakayama K, Sugimoto Y, Ichikawa A, Tanaka S: Activation of histidine decarboxylase through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815. J Biol Chem; 2007 May 4;282(18):13438-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of histidine decarboxylase through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815.
  • We investigated the processing of HDC in a mouse mastocytoma, P-815, using a lentiviral expression system.
  • Treatment with butyrate caused an increase in the enzyme activity of the cells expressing the wild type HDC, but not in the cells expressing the processing-incompetent mutant.
  • Processing and enzymatic activation of HDC in P-815 cells was enhanced in the presence of a Zn(2+) chelator, TPEN.
  • Although treatment with butyrate and TPEN drastically augmented the protease activity of caspase-3, and -9, no apoptotic cell death was observed.
  • These results suggest that, in P-815 cells, histamine synthesis is augmented through the post-translational cleavage of HDC, which is mediated by caspase-9.
  • [MeSH-major] Apoptosis. Caspase 9 / metabolism. Histidine Decarboxylase / metabolism. Mastocytoma / enzymology. Neoplasm Proteins / metabolism. Protein Processing, Post-Translational
  • [MeSH-minor] Animals. Aspartic Acid / genetics. Aspartic Acid / metabolism. Caspase 3 / genetics. Caspase 3 / metabolism. Cell Line, Tumor. Chelating Agents / pharmacology. Ethylenediamines / pharmacology. Histamine / biosynthesis. Humans. Lentivirus. Mice. Protease Inhibitors / pharmacology. Protein Precursors / genetics. Protein Precursors / metabolism. Zinc / metabolism

  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17360717.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Protein Precursors; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; 30KYC7MIAI / Aspartic Acid; 820484N8I3 / Histamine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 4.1.1.22 / Histidine Decarboxylase; J41CSQ7QDS / Zinc
  •  go-up   go-down


6. Sasai K, Katoh M, Fujita D, Yamashita M, Constantinoiu CC, Matsubayashi M, Tani H, Baba E: Monoclonal antibodies for the diagnosis of canine mastocytoma. Hybridoma (Larchmt); 2007 Jun;26(3):162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies for the diagnosis of canine mastocytoma.
  • Mastocytomas are the most common malignant neoplasm in the dog; they are more aggressive than the mast cell tumors of other species.
  • Therefore, it is imperative to develop a highly sensitive and specific immunoassay for clinical diagnosis of canine mastocytoma.
  • The production and characterization of new mouse monoclonal antibodies (MAb 9-3 and MAb 80) directed against canine mastocytoma are reported here.
  • By immunohistochemistry using fresh frozen tissue of tissue impression smears, we observed that the antigen recognized by MAb 9-3 is expressed exclusively on the surface and cytoplasmic granules of canine mastocytoma but not on the mast cells in normal canine skin.
  • MAb 80 did not compete for binding to mast cells in normal canine skin.
  • Western blot assays performed with canine mastocytoma indicated that MAb 9-3 recognized the 74 kDa band, and MAb 80 recognized the 167 and 248 kDa bands.
  • We studied the immunostaining pattern of impression smears with MAb 9-3 from 36 benign and malignant canine masses, including eight samples of mastocytoma that were positive and other tumor samples that were negative by MAb 9-3.
  • This report for the first time precisely characterizes a monoclonal antibody specific for canine mastocytoma, facilitating clinical and molecular investigation of canine mastocytoma.
  • [MeSH-major] Antibodies, Monoclonal. Dog Diseases / diagnosis. Mast-Cell Sarcoma / veterinary
  • [MeSH-minor] Animals. Antigens, Neoplasm. Cross Reactions. Dogs. Female. Hybridomas / immunology. Male. Mast Cells / immunology. Mastocytoma / diagnosis. Mastocytoma / immunology. Mastocytoma / veterinary. Mice. Mice, Inbred BALB C. Skin / immunology. Skin Neoplasms / diagnosis. Skin Neoplasms / immunology. Skin Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600498.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm
  •  go-up   go-down


7. Leadbeater JC, Gutierrez-Nibeyro SD, Brown JA: Mastocytoma in the common carpal sheath of the digital flexor tendons of a horse. Aust Vet J; 2010 Jan;88(1-2):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mastocytoma in the common carpal sheath of the digital flexor tendons of a horse.
  • Tenoscopic exploration confirmed the presence of a capsulated soft tissue mass.
  • Thecotomy was required to fully debride the mass, which histology revealed to be a mast cell tumour.
  • At 22 months postoperatively, the horse developed mild right forelimb lameness and eosinophilic tenosynovitis because of recurrence of the mastocytoma.
  • Mastocytosis is a possible differential diagnosis in any horse exhibiting lameness associated with tenosynovitis.
  • [MeSH-major] Horse Diseases / diagnosis. Horse Diseases / surgery. Mastocytoma / veterinary. Tenosynovitis / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148821.001).
  • [ISSN] 1751-0813
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Matsumoto M, Ikeda M, Takeya M, Kodama H: Plane xanthoma associated with multiple mastocytoma. Pediatr Dermatol; 2007 Sep-Oct;24(5):E66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plane xanthoma associated with multiple mastocytoma.
  • The brown macules showed infiltration of a large number of mast cells and a small number of scattered foam cells, whereas in the yellowish plaques, the number of foam cells was greatly increased.
  • Immunohistochemical analysis found that the foam cells were stained with monocyte/macrophage markers including HAM56, and with SRA-C6, a monoclonal antibody to macrophage scavenger receptor class A (CD204).
  • Therefore, the yellowish plaques were considered to be plane xanthoma associated with cutaneous mastocytoma.
  • [MeSH-minor] Foam Cells / pathology. Humans. Infant. Male. Mast Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958784.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Elders RC, Baines SJ, Catchpole B: Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Vet Immunol Immunopathol; 2009 Jul 15;130(1-2):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which preferentially induces apoptosis in cells that have undergone malignant transformation.
  • In humans, non-neoplastic cells are normally protected from the effects of TRAIL by expressing decoy receptors, lacking death domains.
  • In contrast, neoplastic cells tend to downregulate their decoy receptor expression, increasing their susceptibility to the pro-apoptotic effects of TRAIL, via the functional TRAIL receptors.
  • The aim of the current study was to investigate the effect of TRAIL on the canine C2 mastocytoma cell line to determine whether this agent might be a suitable treatment for mast cell tumors in dogs.
  • C2 and MDCK cells were cultured with recombinant human TRAIL.
  • Cell metabolism was assessed using a colorimetric MTT-based assay.
  • C2 cells demonstrated greater sensitivity to TRAIL-induced apoptosis compared to MDCK cells by all assessment methods.
  • C2, but not MDCK, cells expressed mRNA for TNFRSF11B, detected by RT-PCR.
  • In other species, TNFRSF11B is a decoy receptor, as even though it has a death domain it is secreted due to its lack of a transmembrane domain.
  • The effect of TRAIL on the C2 cell line suggests that this cytokine might be suitable for treatment of mast cell tumors in dogs.
  • [MeSH-major] Apoptosis / drug effects. Dog Diseases / drug therapy. Mastocytoma / veterinary. Skin Neoplasms / veterinary. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Animals. Caspase 3 / metabolism. Caspase 7 / metabolism. Cell Line, Tumor. Cell Survival / immunology. Dogs. Flow Cytometry / veterinary. Osteoprotegerin / chemistry. Osteoprotegerin / genetics. Polymerase Chain Reaction / veterinary. Recombinant Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185923.001).
  • [ISSN] 1873-2534
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Osteoprotegerin; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF11B protein, human; 0 / TNFSF10 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down


10. Mederle O, Mederle N, Bocan EV, Ceauşu R, Raica M: VEGF expression in dog mastocytoma. Rev Med Chir Soc Med Nat Iasi; 2010 Jan-Mar;114(1):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF expression in dog mastocytoma.
  • The biologic behavior of mastocytomas is highly variable; some tumors have a benign behavior, whereas others exhibit aggressive growth and metastasis.
  • Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells in various malignancies.
  • MATERIAL AND METHOD: In the present study, we have investigated expression of VEGF in cutaneous tumor from a dog and combined immunohistochemical expression of VEGF with mast cell tryptase, CD117 and vimentin.
  • RESULTS: Tumor cells were positive for VEGF, and inflammatory cells were negative.
  • VEGF expression was found in tumor cells as a heterogeneous positive reaction, with cytoplasmic pattern and moderate to strong in intensity.
  • Arrangement of tumor cells was in clusters, in deepest part, close to the proliferation front.
  • The dog died 5 month from the diagnosis, and our observation suggest that VEGF secretion by tumor cells correlates with unfavorable prognosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Dog Diseases / metabolism. Mastocytoma / veterinary. Skin Neoplasms / veterinary. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509299.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


11. Salces IG, Alfaro J, Sáenz DE Santamaría MC, Sanchez M: Scabies presenting as solitary mastocytoma-like eruption in an infant. Pediatr Dermatol; 2009 Jul-Aug;26(4):486-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scabies presenting as solitary mastocytoma-like eruption in an infant.
  • We report a case in which the initial clinical finding was a solitary cutaneous nodule on the wrist of a young infant which urticated when rubbed, and was diagnosed as a solitary mastocytoma.
  • Two months later, she had the onset of a new vesiculo-pustular eruption on the palms and soles, consistent with scabies infestation and treatment with topical permethrin 5% cream resulted in resolution of the entire eruption, including the primary nodule.
  • While scabies has been reported to mimick a variety of conditions including urticaria pigmentosa, to our knowledge no previous cases masquerading as solitary mastocytoma have been reported.
  • [MeSH-major] Mastocytoma, Skin / pathology. Scabies / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Scabies.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PERMETHRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689539.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insecticides; 0 / Ointments; 509F88P9SZ / Permethrin
  •  go-up   go-down


12. Tuxen AJ, Orchard D: Solitary mastocytoma occurring at a site of trauma. Australas J Dermatol; 2009 May;50(2):133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary mastocytoma occurring at a site of trauma.
  • We describe a patient with a solitary mastocytoma arising at a site of trauma.
  • The patient was born with the umbilical cord wrapped around her right thigh and subsequently developed a solitary mastocytoma in the exact site and distribution of this injury.
  • The pathogenesis of mast cell proliferation in solitary mastocytoma is not completely understood.
  • Cytokines released after injury, such as stem cell factor, may stimulate the proliferation of mast cells, as well as fibroblasts and melanocytes to form a mastocytoma.
  • Mast cells in a newborn may be more sensitive to stem cell factor in the presence of cytokines released after injury due to an increased density of c-kit receptors.
  • [MeSH-major] Birth Injuries / physiopathology. Mastocytoma, Skin / diagnosis. Mastocytoma, Skin / etiology. Thigh / injuries. Wound Healing / physiology

  • Hazardous Substances Data Bank. BETAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397569.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 826Y60901U / betamethasone-17,21-dipropionate; 9842X06Q6M / Betamethasone; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


13. Benamar M, Melhaoui A, Zyad A, Bouabdallah I, Aziz M: Anti-cancer effect of two alkaloids: 2R and 2S-bgugaine on mastocytoma P815 and carcinoma Hep. Nat Prod Res; 2009;23(7):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-cancer effect of two alkaloids: 2R and 2S-bgugaine on mastocytoma P815 and carcinoma Hep.
  • Tozz. (Araceae), and its isomer S-bgugaine, obtained by an asymmetric synthesis, were examined for their cytotoxic activities on two cancerous cellular lines: the murine mastocytoma cell line P815 and the human laryngeal carcinoma cell line Hep.
  • The concentrations required to induce 50% of lysis (IC(50)) for R-bgugaine and S-bgugaine alkaloids were determined, and are 10 and 5 microg mL(-1), and 5 and 100 microg mL(-1), respectively, for the mastocytoma P815 and carcinoma Hep, compared with those of Adriamycine (5 microg mL(-1) for P815 cell line and 5 microg mL(-1) for Hep cell line), taken as positive controls.
  • [MeSH-minor] Animals. Cell Death / drug effects. Cell Line, Tumor. Humans. Inhibitory Concentration 50. Mice. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401921.001).
  • [ISSN] 1478-6427
  • [Journal-full-title] Natural product research
  • [ISO-abbreviation] Nat. Prod. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents; 0 / Cytotoxins; 0 / Pyrrolidines; 0 / bgugaine
  •  go-up   go-down


14. Tran DT, Jokinen CH, Argenyi ZB: Histiocyte-rich pleomorphic mastocytoma: an uncommon variant mimicking juvenile xanthogranuloma and Langerhans cell histiocytosis. J Cutan Pathol; 2009 Nov;36(11):1215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocyte-rich pleomorphic mastocytoma: an uncommon variant mimicking juvenile xanthogranuloma and Langerhans cell histiocytosis.
  • A biopsy demonstrated a large intradermal nodule composed of unusually large epithelioid mast cells, including a prominent subset with bi-lobed and multi-lobed nuclei.
  • By immunohistochemistry, the cells expressed CD117 (C-Kit), mast cell tryptase, CD68, and CD25, and were negative for CD163, CD1a, and S-100, confirming the diagnosis of mastocytoma.
  • Equally prominent was an admixed infiltrate of CD68 and CD163-positive xanthomatous histiocytes that included Touton-type giant cells.
  • However, given the unusual cytologic features, close clinical observation is warranted, as the long-term biologic potential of mastocytoma with this degree of cytologic atypia is uncertain.
  • Awareness of this unusual morphologic variant is also important as the histologic features may mimic such childhood neoplasms as juvenile xanthogranuloma and Langerhans cell histiocytosis.
  • [MeSH-major] Histiocytes / pathology. Mastocytoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Histiocytosis, Langerhans-Cell / pathology. Humans. Immunohistochemistry. Neck / pathology. Xanthogranuloma, Juvenile / pathology


15. Jakab C, Szász AM, Kulka J, Schaff Z, Rusvai M, Németh T, Gálfi P: Cutaneous mast cell tumour within a lipoma in a boxer. Acta Vet Hung; 2009 Jun;57(2):263-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous mast cell tumour within a lipoma in a boxer.
  • This report describes a case of a canine cutaneous grade I mast cell tumour which developed within a lipoma in the right axillar region of an 8-year-old male Boxer.
  • Immunohistologically, the neoplastic mast cells were positive for serotonin, CD45 vimentin and p53, and negative for lysozyme, CD3 and CD79a expression.
  • The proliferation index of the mast cell tumour based on the Ki-67 antigen was 6.1%.
  • Between the benign neoplastic lipocytes and mastocytoma tumour cells intratumoural microvessels were detected by immunohistochemical staining using CD31 and claudin-5 as markers for vascular endothelium.
  • [MeSH-major] Dog Diseases / pathology. Lipoma / veterinary. Mastocytoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584039.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


16. Fulciniti F, Di Mattia D, Curcio MP, Bove P, Rota AM, Botti G: Canine mastocytoma: report of 8 cases diagnosed by fine needle cytology and clinicopathologic correlations. Acta Cytol; 2007 Jul-Aug;51(4):616-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine mastocytoma: report of 8 cases diagnosed by fine needle cytology and clinicopathologic correlations.
  • BACKGROUND: Mast cell proliferations are commoner in dogs than in humans; mass forming lesions in the former are apt to fine needle sampling and the obtained cytopathological picture might be informing to enhance recognition of similar proliferations in humans.
  • CASE: Clinical and cytopathologic data were collected from 8 cases of canine mastocytomas diagnosed by fine needle cytology.
  • In all cases the cytopathological diagnosis was confirmed by histopathologic examination of the excised mass, by necropsy or by response to therapy.
  • CONCLUSION: There are marked similarities between canine and human mastocytomas, despite possible differences in the clinical course of the disease in both species.
  • Canine mastocytomas may hence be used as an animal model of a human disease and, as such, familiarity with their cytologic presentation may be useful for recognizing mast cell proliferations in humans.
  • [MeSH-major] Dog Diseases / diagnosis. Dog Diseases / pathology. Mastocytoma / diagnosis. Mastocytoma / veterinary
  • [MeSH-minor] Animals. Biopsy, Fine-Needle. Dogs. Female. Immunohistochemistry. Immunophenotyping. Lymph Nodes / pathology. Male. Mast Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718137.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Krishnan KR, Ownby DR: A solitary mastocytoma presenting with urticaria and angioedema in a 14-year-old boy. Allergy Asthma Proc; 2010 Nov-Dec;31(6):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A solitary mastocytoma presenting with urticaria and angioedema in a 14-year-old boy.
  • The differential diagnosis for urticaria is broad, making the evaluation and pinpointing the underlying cause difficult and frustrating for both families and physicians.
  • Mastocytosis is a rare disease that very seldom presents with urticaria but may be associated with significant morbidity and mortality if not recognized in a timely manner.
  • We are presenting a case of a 14-year-old boy who presented with urticaria and angioedema possibly caused by a solitary mastocytoma.
  • The learning points from this case are that mastocytosis should be considered in the differential diagnosis of urticaria and solitary mastocytomas may remain active into adolescence, raising concern for systemic progression.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21708063.001).
  • [ISSN] 1539-6304
  • [Journal-full-title] Allergy and asthma proceedings
  • [ISO-abbreviation] Allergy Asthma Proc
  • [Language] ENG
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


18. Fujimi K, Uehara Y, Abe S, Kawamura A, Devarajan S, Miura S, Saku K, Urata H: Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells. Hypertens Res; 2010 Feb;33(2):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells.
  • In this study, we tested whether oxidative stress upregulates mouse mast cell proteinase chymase, mouse mast cell proteinase (MMCP)-5 or MMCP-4.
  • Cultured mouse mastocytoma cells (MMC) displaying chymase-dependent Ang II-forming activity were treated with H(2)O(2) and several aminothiols with or without anti-oxidants.
  • Homocysteine increased mast cell chymase expression and activity through the mechanism of oxidative stress.
  • [MeSH-major] Chymases / genetics. Homocysteine / pharmacology. Mastocytoma / enzymology. Oxidative Stress
  • [MeSH-minor] Angiotensin II / biosynthesis. Animals. Cell Line, Tumor. Mice. RNA, Messenger / analysis. Reactive Oxygen Species / metabolism. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960020.001).
  • [ISSN] 1348-4214
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0LVT1QZ0BA / Homocysteine; 11128-99-7 / Angiotensin II; EC 3.4.21.39 / Chymases
  •  go-up   go-down


19. Hunter MJ, Iodice MW, Pathak AK, Street MA, Helm BA: Characterization of an early signaling defect following Fc epsilonRI activation in the canine mastocytoma cell line, C2. Mol Immunol; 2009 Mar;46(6):1260-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of an early signaling defect following Fc epsilonRI activation in the canine mastocytoma cell line, C2.
  • A comparison of IgE recognition by cognate receptors expressed on the C2 canine mastocytoma cell line with analogous events in a rat basophilic leukemia cell line transfected with the alpha-chain subunit of the canine high-affinity IgE receptor using flow cytometry show that canine IgE recognizes the alpha-chain of its cognate receptor on both cell lines.
  • Our study confirms the expression of functional IgE receptors in both cell lines, but receptor-mediated signaling in the C2 line only supports the early stages of downstream signaling as shown by the phosphorylation of the gamma-chain and the failure to effect the phosphorylation of Syk.
  • In contrast RBL-2H3 cells respond to sensitization with IgE and challenge with cognate antigen with tyrosine phosphorylation of the gamma-subunits of the receptor complex followed by downstream phosphorylation of Syk and Ca(2+) mobilization, culminating in beta-hexosaminidase release.
  • We propose that the identification of the precise signaling defect in C2 cells will yield useful information regarding the pathway leading to mast cell exocytosis and facilitate the restoration of the complete signaling cascade through complementation of the missing/defective signal transducer since signaling events downstream of Ca(2+) mobilization are intact as demonstrated by beta-hexosaminidase release following non-immunologic stimulation with the calcium ionophore, A23187.
  • [MeSH-major] Mast Cells / physiology. Receptors, IgE / metabolism
  • [MeSH-minor] Animals. Calcimycin / pharmacology. Cell Line, Tumor. Dogs. Exocytosis. Intracellular Signaling Peptides and Proteins / metabolism. Mastocytoma. Phosphorylation. Protein-Tyrosine Kinases / metabolism. Rats. Signal Transduction. beta-N-Acetylhexosaminidases / secretion

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135724.001).
  • [ISSN] 1872-9142
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBSQ/Q/2005/06706
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, IgE; 37H9VM9WZL / Calcimycin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


20. Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P: Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol; 2008 Nov;36(11):1461-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
  • OBJECTIVE: Advanced mast cell (MC) neoplasms are usually resistant to conventional therapy.
  • Mastocytomas in dogs often behave as aggressive tumors.
  • We report that heat-shock protein 32 (Hsp32), also known as heme oxygenase-1, is a survival-enhancing molecule and new target in canine mastocytoma cells.
  • MATERIALS AND METHODS: As assessed by reverse transcriptase polymerase chain reaction, Northern blotting, immunocytochemistry, and Western blotting, primary neoplastic dog MC, and the canine mastocytoma-derived cell line C2 expressed Hsp32 mRNA and the Hsp32 protein in a constitutive manner.
  • RESULTS: The KIT-targeting drug midostaurin inhibited expression of Hsp32, as well as survival in C2 cells.
  • Confirming the functional role of Hsp32, the inhibitory effect of midostaurin on C2 cells was markedly reduced by the Hsp32-inductor hemin.
  • Both drugs were found to inhibit proliferation of C2 cells as well as growth of primary neoplastic canine MC.
  • [MeSH-major] Apoptosis / drug effects. Heme Oxygenase-1 / antagonists & inhibitors. Mastocytoma / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Dogs. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / metabolism. RNA, Messenger / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723263.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.99.3 / Heme Oxygenase-1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


21. Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P: Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol; 2007 Feb 15;115(3-4):320-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
  • Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells in various malignancies.
  • In the present study, we have investigated expression of VEGF and VEGF receptors in canine mastocytomas and the canine mastocytoma cell line C2.
  • As assessed by immunostaining of tissue sections and cytospin slides, primary neoplastic mast cells (MC) and C2 cells were found to express the VEGF protein.
  • In Northern blot and RT-PCR experiments, C2 cells expressed VEGF mRNA in a constitutive manner.
  • VEGF mRNA expression in C2 cells was counteracted by LY294002 and rapamycin, suggesting involvement of the PI3-kinase/mTOR pathway.
  • Moreover, C2 cells were found to express VEGF receptor-1 (Flt-1) and VEGF receptor-2 (KDR).
  • However, recombinant VEGF failed to promote (3)H-thymidine uptake in C2 cells, and a neutralizing anti-VEGF antibody (bevacizumab) failed to downregulate spontaneous proliferation in these cells.
  • In addition, rapamycin decreased the expression of VEGF in C2 cells at the mRNA and protein level without suppressing their proliferation.
  • Together, canine mastocytoma cells express VEGF as well as VEGF receptors.
  • However, despite co-expression of VEGF and its receptors, VEGF is not utilized as an autocrine growth regulator by canine mastocytoma cells.
  • [MeSH-major] Dog Diseases / metabolism. Mastocytoma / veterinary. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor Receptor-1 / biosynthesis. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Bevacizumab. Blotting, Northern / veterinary. Cell Line, Tumor. Chromones / pharmacology. Dogs. Female. Flavonoids / pharmacology. Flow Cytometry / veterinary. Immunohistochemistry / veterinary. Male. Morpholines / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinase Inhibitors / pharmacology. RNA / chemistry. RNA / genetics. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Sirolimus / pharmacology

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196258.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Chromones; 0 / Flavonoids; 0 / Morpholines; 0 / Protein Kinase Inhibitors; 0 / Vascular Endothelial Growth Factor A; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2S9ZZM9Q9V / Bevacizumab; 63231-63-0 / RNA; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


22. Bussmann C, Hagemann T, Hanfland J, Haidl G, Bieber T, Novak N: Flushing and increase of serum tryptase after mechanical irritation of a solitary mastocytoma. Eur J Dermatol; 2007 Jul-Aug;17(4):332-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flushing and increase of serum tryptase after mechanical irritation of a solitary mastocytoma.
  • Solitary mastocytomas are infiltrates of mast cells in the upper corium, appearing at any side of the body as brownish-reddish plaques in the first months of life.
  • We conclude that uncontrolled stroking of mastocytomas should be avoided in patients with a systemic reaction in their history, since this case demonstrates that despite its limited size, mechanical irritation of a solitary mastocytoma may induce strong systemic symptoms as witnessed by transient increase of the serum tryptase, which to our knowledge has not been described in the literature before.
  • [MeSH-major] Flushing / etiology. Mastocytoma / blood. Mastocytoma / complications. Tryptases / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540642.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.59 / Tryptases
  •  go-up   go-down


23. Sekis I, Gerner W, Willmann M, Rebuzzi L, Tichy A, Patzl M, Thalhammer JG, Saalmüller A, Kleiter MM: Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line. Am J Vet Res; 2009 Sep;70(9):1141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line.
  • OBJECTIVE: To establish the radiosensitivity and effect of irradiation on vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) expression in the canine mastocytoma cell line C2.
  • SAMPLE POPULATION: Canine mastocytoma cell line C2.
  • PROCEDURES: C2 cells were irradiated with single doses of 2, 4, 6, and 8 Gy.
  • RESULTS: C2 cells secreted VEGF constitutively.
  • Cell survival rates decreased in a dose-dependent manner.
  • The apoptotic cell fraction had a dose-dependent increase that reached its maximum 24 to 48 hours after radiation.
  • CONCLUSIONS AND CLINICAL RELEVANCE: The C2 cell line was radiosensitive, and a fraction (up to 40%) of cells died via apoptosis in a dose-dependent manner.
  • In response to radiation, C2 cells did not upregulate VEGF production or VEGFR.
  • Further studies are needed to determine whether tumor control could be improved by combining radiotherapy with VEGFR inhibitors or apoptosis-modulating agents.
  • [MeSH-major] Dog Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Animals. Annexin A5 / genetics. Apoptosis / radiation effects. Cell Division / radiation effects. Cell Line, Tumor. Dogs. Dose-Response Relationship, Radiation. Humans. Vascular Endothelial Growth Factor Receptor-1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719431.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


24. Schmutzler S, Bachmann L, Fuhrmann H, Schumann J: PUFA-dependent alteration of oxidative parameters of a canine mastocytoma cell line. Acta Vet Hung; 2010 Dec;58(4):453-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PUFA-dependent alteration of oxidative parameters of a canine mastocytoma cell line.
  • Mast cells play a key role in the immune response.
  • Thereby, the balance of oxidative metabolism is of importance in mast cell mediator synthesis and release.
  • Fatty acids may modify mast cell function in several ways.
  • In this study, we investigated the influence of polyunsaturated fatty acids (PUFAs) on oxidative parameters of a canine mastocytoma cell line.
  • C2 cells were cultured in media supplemented with linoleic acid, arachidonic acid, alpha-linolenic acid and eicosapentaenoic acid, respectively.
  • Exposure of the cells to PUFAs resulted in a significant increase in the synthesis of both ROS and lipid peroxides.
  • Distinct differences between the PUFAs tested underline the impact of the unsaturation degree of fatty acids as well as the position of double bonds on mast cells.
  • [MeSH-major] DNA Damage / drug effects. Fatty Acids, Unsaturated / pharmacology. Lipid Peroxidation / drug effects. Mast Cells / drug effects. Mastocytoma / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Oxidation-Reduction. Peptides / pharmacology. Reactive Oxygen Species / metabolism. Wasp Venoms / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21087915.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Fatty Acids, Unsaturated; 0 / Peptides; 0 / Reactive Oxygen Species; 0 / Wasp Venoms; 72093-21-1 / mastoparan
  •  go-up   go-down


25. Seidel A, Gueck T, Fuhrmann H: The Influence of long-chain polyunsaturated fatty acids on total lipid fatty acid composition of a canine mastocytoma cell line. J Vet Med A Physiol Pathol Clin Med; 2005 Jun;52(5):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Influence of long-chain polyunsaturated fatty acids on total lipid fatty acid composition of a canine mastocytoma cell line.
  • Cutaneous mast cells are considered as key immune effectors in the pathogenesis of canine atopic dermatitis (CAD).
  • These cells release immediate-phase and late-phase mediators of inflammation.
  • The purpose of this study was to examine the effects of n6- and n3-fatty acids on the fatty acid composition of canine mastocytoma cells (C2) as a possible model for CAD.
  • Cell growth was examined for 11 days in all media.
  • Cell growth increased from days 1 to 8 and decreased thereafter in all media conditions.
  • The fatty acids supplied did not influence cell growth.
  • The cells were harvested after 8 days for fatty acid analysis.
  • [MeSH-major] Dermatitis, Atopic / veterinary. Disease Models, Animal. Dog Diseases / pathology. Fatty Acids, Unsaturated / pharmacology. Inflammation Mediators / metabolism. Mast Cells / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Docosahexaenoic Acids / administration & dosage. Docosahexaenoic Acids / pharmacology. Dogs. Mastocytoma / pathology. Mastocytoma / veterinary. gamma-Linolenic Acid / administration & dosage. gamma-Linolenic Acid / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943605.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Unsaturated; 0 / Inflammation Mediators; 25167-62-8 / Docosahexaenoic Acids; 78YC2MAX4O / gamma-Linolenic Acid
  •  go-up   go-down


26. Kataoka H, Sakanaka M, Semma M, Yamamoto T, Hirota S, Tanaka S, Ichikawa A: PGE2-receptor subtype EP4-dependent adherence of mastocytoma P-815 cells to matrix components in subcutaneous tissues overlaying inside surface of air pouch cavity in CDF1 mouse. Inflamm Res; 2008 Aug;57(8):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PGE2-receptor subtype EP4-dependent adherence of mastocytoma P-815 cells to matrix components in subcutaneous tissues overlaying inside surface of air pouch cavity in CDF1 mouse.
  • OBJECTIVES: It remains to be fully clarified how adhesion of mast cells is regulated in vivo.
  • We previously reported that PGE2-receptor EP4 stimulated the adhesion of mouse mastocytoma P-815 cells to plate-bound fibronectin.
  • METHODS: P-815 cells were transplanted in an air pouch produced in the transplantable mice, CDF1.
  • The number of cells that adhere to the subcutaneous tissues overlaying the inside cavity surface was determined.
  • RESULTS: The number of adhered cells was decreased in mice administered with ibuprofen or an EP4 antagonist, ONO AE3-208.
  • A local administration of PGE(2) or a phorbol ester, PMA, increased the number of adhered cells, which was also suppressed in the mice treated with ONO AE3-208.
  • CONCLUSION: Our results suggest that PGE(2)-mediated adhesion of P-815 cells in the subcutaneous tissues of the air pouch is mediated by the EP4 subtype.
  • [MeSH-major] Cell Adhesion / physiology. Extracellular Matrix / metabolism. Mastocytoma. Receptors, Prostaglandin E / metabolism. Subcutaneous Tissue / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cyclooxygenase Inhibitors / metabolism. Ibuprofen / metabolism. Male. Mast Cells / cytology. Mast Cells / metabolism. Mice. Mice, Inbred Strains. Naphthalenes / metabolism. Phenylbutyrates / metabolism. Receptors, Prostaglandin E, EP4 Subtype. Tetradecanoylphorbol Acetate / metabolism

  • Guide to Pharmacology. gene/protein/disease-specific - EP4 receptor - data and references .
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787774.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid; 0 / Cyclooxygenase Inhibitors; 0 / Naphthalenes; 0 / Phenylbutyrates; 0 / Ptger4 protein, mouse; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; NI40JAQ945 / Tetradecanoylphorbol Acetate; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


27. Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, Tajara EH, Christian HC, Oliani SM: Annexin 1: differential expression in tumor and mast cells in human larynx cancer. Int J Cancer; 2007 Jun 15;120(12):2582-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin 1: differential expression in tumor and mast cells in human larynx cancer.
  • Annexin 1 protein (ANXA1) expression was evaluated in tumor and mast cells in human larynx cancer and control epithelium.
  • The effect of the exogenous ANXA1 (peptide Ac 2-26) was also examined during the cellular growth of the Hep-2 human larynx epidermoid carcinoma cell line.
  • This peptide inhibited the proliferation of the Hep-2 cells within 144 hr.
  • In surgical tissue specimens from 20 patients with larynx cancer, ultrastructural immunocytochemistry analysis showed in vivo down-regulation of ANXA1 expression in the tumor and increased in mast cells and Hep-2 cells treated with peptide Ac2-26.
  • Combined in vivo and in vitro analysis demonstrated that ANXA1 plays a regulatory role in laryngeal cancer cell growth.
  • We believe that a better understanding of the regulatory mechanisms of ANXA1 in tumor and mast cells may lead to future biological targets for the therapeutic intervention of human larynx cancer.
  • [MeSH-major] Annexin A1 / genetics. Gene Expression Profiling. Laryngeal Neoplasms / pathology. Mast Cells / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Epithelial Cells / metabolism. Epithelial Cells / ultrastructure. Gene Expression / drug effects. Humans. Immunohistochemistry. Larynx / metabolism. Larynx / pathology. Larynx / ultrastructure. Male. Microscopy, Immunoelectron. Middle Aged. Peptides / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tryptases / genetics. Tryptases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340616.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Peptides; 0 / RNA, Messenger; 0 / annexin A1 peptide (2-26); EC 3.4.21.59 / Tryptases
  •  go-up   go-down


28. Yee SB, Baek SJ, Park HT, Jeong SH, Jeong JH, Kim TH, Kim JM, Jeong BK, Park BS, Kwon TK, Yoon I, Yoo YH: zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells. Exp Mol Med; 2006 Dec 31;38(6):634-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells.
  • In a preliminary study, we found that benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD- fmk), unlike Boc-aspartyl(OMe)-fluoromethylketone (BocD-fmk), at usual dosage could not prevent genistein-induced apoptosis of p815 mastocytoma cells.
  • We observed that 14-3-3 protein level was reduced in genistein-treated cells and that BocD-fmk but not zVAD-fmk prevented the reduction of 14-3-3 protein level and the release of Bad from 14-3-3.
  • We also demonstrated that truncated Bad to Bcl-xL interaction in genistein- treated cells was prevented by BocD-fmk but not by zVAD-fmk treatment.
  • Our data shows that caspase-6 plays a role on Bad/14-3-3 pathway in genistein-induced apoptosis of p815 cells, and that the usual dose of zVAD-fmk, in contrast to BocD-fmk, did not prevent caspase-6 acting on 14-3-3/Bad-mediated event.
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Animals. Caspase Inhibitors. Cell Line, Tumor. Genistein / pharmacology. Mastocytoma. Mice. Mitochondria / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202839.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Amino Acid Chloromethyl Ketones; 0 / Benzyl Compounds; 0 / Boc-D-FMK; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Hydrocarbons, Fluorinated; 0 / bcl-Associated Death Protein; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; DH2M523P0H / Genistein; EC 3.4.22.- / Caspase 6
  •  go-up   go-down


29. Zou W, Hu TH: [Relation of tumor associated macrophages and mast cells of tumor interstitial and angiogenesis in non-small cell lung cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Dec;32(6):1037-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation of tumor associated macrophages and mast cells of tumor interstitial and angiogenesis in non-small cell lung cancer].
  • OBJECTIVE: To detect tumor microvessel count (MVC), tumor associated macrophage (TAM) and Mast cell (MC) counts, and to explore their correlation and the clinical significance in non-small cell lung cancer (NSCLC).
  • RESULTS: The counts of microvessel, TAMs, and MCs in the NSCLC tissues were apparently higher than those of the normal tissues, and these counts increased with the development of T stage and clinical stage, metastasis of the tumor, and the reduction of the patient survival time.
  • CONCLUSION: Tumor interstitial infiltrating inflammatory cells, TAMs and MCs can cooperatively promote the tumor angiogenesis,which associates with the development, invasion, metastasis and prognosis of NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood supply. Lung Neoplasms / blood supply. Macrophages / cytology. Mast Cells / cytology. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182723.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC: Role of mast cells in tumor growth. Ann Clin Lab Sci; 2007;37(4):315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of mast cells in tumor growth.
  • The growth of malignant tumors is determined in large part by the proliferative capacity of the tumor cells.
  • Clinical observations and animal experiments have established that tumor cells elicit immune responses.
  • Histopathologic studies show that many tumors are surrounded by mononuclear cell and mast cell infiltrates.
  • Mast cells are ubiquitous in the body and are critical for allergic reactions.
  • Increasing evidence indicates that mast cells secrete proinflammatory cytokines and are involved in neuro-inflammatory processes and cancer.
  • Mast cells accumulate in the stroma surrounding certain tumors, especially mammary adenocarcinoma, and the molecules they secrete can benefit the tumor.
  • However, mast cells can also increase at the site of tumor growth and participate in tumor rejection.
  • Mast cells may be recruited by tumor-derived chemoattractants and selectively secrete molecules such as growth factors, histamine, heparin, VEGF, and IL-8, as well as proteases that permit the formation of new blood vessels and metastases.
  • Tumor mast cell intersections play regulatory and modulatory roles affecting various aspects of tumor growth.
  • Discovery of these new roles of mast cells further complicates the understanding of tumor growth.
  • This review focuses on the strategic importance of mast cells to the progression of tumors, and proposes a revised immune effector mechanism of mast cell involvement in tumor growth.
  • [MeSH-major] Mast Cells / immunology. Neoplasms / physiopathology
  • [MeSH-minor] Cell Proliferation. Cytokines / metabolism. Cytokines / secretion. Histamine / metabolism. Humans. Neovascularization, Pathologic / immunology

  • MedlinePlus Health Information. consumer health - Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000287.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 820484N8I3 / Histamine
  • [Number-of-references] 50
  •  go-up   go-down


31. Bağriaçik EÜ, Uslu K, Yurtçu E, Stefek M, Karasu C: Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int; 2007 Sep;31(9):979-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells.
  • Doxorubicin (DOXO), a widely used chemotherapeutic agent, induces apoptosis in transformed and non-transformed cells.
  • In the present study we investigated the effects of stobadine, a pyridoindole antioxidant in a DOXO-induced apoptosis model of P815 cells by flow cytometric analyses and by measuring caspase-3 and caspase-9 activities.
  • Pretreating cells with stobadine significantly increased cell viability and decreased apoptosis rate.
  • Inhibition in apoptosis was observed at maximum levels following treatment of cells with 10(-7)M stobadine as evident from flow cytometric analyses.
  • We found that the antioxidative effects of stobadine were comparable to the effects of a well known antioxidant, N-acetyl l-cysteine (NAC).
  • [MeSH-major] Apoptosis / drug effects. Carbolines / pharmacology. Caspase 9 / metabolism. Doxorubicin / pharmacology. Mastocytoma / enzymology. Mastocytoma / pathology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481927.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Carbolines; 0 / Caspase Inhibitors; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspase 9; WYQ7N0BPYC / Acetylcysteine; Y0EA50IJ3V / dicarbine
  •  go-up   go-down


32. Santoro M, Stacy BA, Morales JA, Gastezzi-Arias P, Landazuli S, Jacobson ER: Mast cell tumour in a giant Galapagos tortoise (Geochelone nigra vicina). J Comp Pathol; 2008 Feb-Apr;138(2-3):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tumour in a giant Galapagos tortoise (Geochelone nigra vicina).
  • A well-differentiated cutaneous mast cell tumour was diagnosed in a subadult female giant Galapagos tortoise.
  • The tumour was a pedunculated, verrucose mass located near the base of the neck.
  • The histological features, which were diagnostic for a mast cell tumour, included abundant intracytoplasmic granules that were stained metachromatically with Giemsa and toluidine blue stains.
  • Mast cell tumours are rare in reptiles, and this is the first description of a mast cell tumour in a chelonian.
  • [MeSH-major] Mast Cells / pathology. Mastocytoma, Skin / veterinary. Skin Neoplasms / veterinary. Turtles

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308330.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Cooper MA, Bennett PF, Laverty PH: Metastatic mast cell tumour in a dog presenting with spinal pain. Aust Vet J; 2009 Apr;87(4):157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mast cell tumour in a dog presenting with spinal pain.
  • The clinical, advanced imaging and surgical features of a case of canine extradural mast cell tumour are presented.
  • Given the frequent occurrence and treatment of cutaneous mast cell tumours in dogs, the finding of spinal metastasis is an important reminder to consider metastatic neoplasia in cases of previously treated cancers presenting with spinal pain.
  • [MeSH-major] Dog Diseases / diagnosis. Dog Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary. Spinal Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Dogs. Euthanasia, Animal. Male. Myelography / veterinary. Pain / diagnosis. Pain / veterinary. Spinal Cord / pathology. Spinal Cord / radiography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335472.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Maxová H, Bacáková L, Eckhardt A, Miksík I, Lisá V, Novotná J, Herget J: Growth of vascular smooth muscle cells on collagen I exposed to RBL-2H3 mastocytoma cells. Cell Physiol Biochem; 2010;25(6):615-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of vascular smooth muscle cells on collagen I exposed to RBL-2H3 mastocytoma cells.
  • The aim of this "in vitro" study was to verify that mast cells (RBL-2H3) as a potent source of a variety of biomolecules which can affect vessel wall remodeling are capable of splitting collagen and then facilitating the growth of vascular smooth muscle cells (VSMC).
  • Collagen I was exposed to RBL-2H3 cells cultured 48 hours under normoxic or hypoxic (3% O(2)) conditions and then seeded with VSMC.
  • The VSMC proliferated with the shortest doubling time and reached the highest cell population density on the collagen pre-modified with hypoxic RBL-2H3 cells.
  • This increased growth activity of VSMC was probably due to the fragmentation of collagen by proteases released from RBL-2H3 cells.
  • Absolute amount of collagen fragments was similar in samples exposed to normoxic and hypoxic RBL-2H3 cells, but the concentration of at least one collagen fragment was significantly higher under hypoxic conditions.
  • Mast cells exposed to hypoxia are more capable to split collagen and facilitate the growth of VSMC.
  • [MeSH-major] Cell Proliferation. Collagen Type I / metabolism. Mast Cells / metabolism. Muscle, Smooth, Vascular / cytology
  • [MeSH-minor] Amino Acid Sequence. Animals. Aorta / cytology. Cell Adhesion. Cell Hypoxia. Cell Line, Tumor. Cells, Cultured. Male. Mastocytoma / metabolism. Molecular Sequence Data. Rats. Rats, Wistar

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20511706.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Collagen Type I
  •  go-up   go-down


35. Rassnick KM, Williams LE, Kristal O, Al-Sarraf R, Baez JL, Zwahlen CH, Dank G: Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). J Am Vet Med Assoc; 2008 Apr 15;232(8):1200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
  • OBJECTIVE: To determine clinical activity and toxic effects of lomustine when used to treat cats with mast cell tumors (MCTs).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cat Diseases / drug therapy. Lomustine / therapeutic use. Lymphoma / veterinary. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Female. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / veterinary. Neoplasm Staging / veterinary. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412534.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


36. Hillman LA, Garrett LD, de Lorimier LP, Charney SC, Borst LB, Fan TM: Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006). J Am Vet Med Assoc; 2010 Oct 15;237(8):936-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006).
  • OBJECTIVE: To describe clinical outcome of dogs with mast cell tumors (MCTs) arising from the oral mucosa, oral mucocutaneous junction, or perioral region of the muzzle and evaluate the potential role of the chemokine receptor type 7 (CCR7) in the biological behavior of these tumors.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that in dogs with MCTs arising from the oral mucosa, oral mucocutaneous junction, or perioral region of the muzzle, the presence of regional lymph node metastasis at the time of diagnosis was a negative prognostic factor.
  • In addition, CCR7 expression in the primary tumor was not significantly associated with the presence of regional lymph node metastasis or survival time.
  • [MeSH-major] Dog Diseases / pathology. Mastocytoma / veterinary. Mouth Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Vet Med Assoc. 2010 Dec 15;237(12):1368 [21229804.001]
  • (PMID = 20946081.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ribatti D, Crivellato E: The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol; 2009;275:89-131
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The controversial role of mast cells in tumor growth.
  • Mast cells (MCs) were first described by Paul Ehrlich (Beiträge zur Theorie und Praxis der Histologischen Färbung, Thesis, Leipzig University, 1878).
  • MCs are also involved in various cell-mediated immune reactions and found in tissues from multiple disease sites, and as a component of the host reaction to bacteria, parasite, and even virus infections.
  • The importance of a possible functional link between chronic inflammation and cancer has long been recognized.
  • As most tumors contain inflammatory cell infiltrates, which often include plentiful MCs, a possible contribution of these cells to tumor development has emerged.
  • In this review, general biology of mast cells, their development, anatomical distribution, and phenotype as well as their secretory products will first be discussed.
  • The specific involvement of MCs in tumor biology and tumor fate will then be considered, with particular emphasis on their capacity to stimulate tumor growth by promoting angiogenesis and lymphangiogenesis.
  • Finally, it is suggested that mast cells may serve as a novel therapeutic target for cancer treatment.
  • [MeSH-major] Mast Cells / physiology. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491054.001).
  • [ISSN] 1937-6448
  • [Journal-full-title] International review of cell and molecular biology
  • [ISO-abbreviation] Int Rev Cell Mol Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 225
  •  go-up   go-down


38. Yancey MF, Merritt DA, Lesman SP, Boucher JF, Michels GM: Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther; 2010 Apr;33(2):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
  • Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell tumors in dogs.
  • The pharmacokinetics of toceranib in client-owned dogs of a variety of pure and mixed breeds with mast cell tumors was similar to that in healthy laboratory dogs.
  • These pharmacokinetic parameters support every-other-day administration of toceranib phosphate at an initial dose of 3.25 mg/kg for the treatment of mast cell tumors in dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444041.001).
  • [ISSN] 1365-2885
  • [Journal-full-title] Journal of veterinary pharmacology and therapeutics
  • [ISO-abbreviation] J. Vet. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 24F9PF7J3R / toceranib phosphate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


39. Zhang X, Mei W, Zhang L, Yu H, Zhao X, Fan X, Qian G, Ge S: Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model. Oncol Rep; 2009 Nov;22(5):1213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
  • A strong CTL response is dependent upon a high level of expression of specific class I major histocompatibility complex (MHC)/peptide complexes at the cell surface.
  • In this study, we modified the P1A tumor cell vaccine by addition of the tumor-associated epitope (TAE)-linked beta2m molecule and co-stimulatory molecule CD80 to improve the efficiency in the application of the vaccine.
  • P815 cell lines stably expressing P1A35-43-linked beta2m molecule and/or CD80 were established after transfection, by selection under G418.
  • Administration of these inactivated tumor cell vaccines allowed the TAE-specific CD8+ T cell responses to be examined in vivo.
  • Our results indicate that immunization with P815 cells expressing both the P1A35-43-linked beta2m molecule and the murine CD80 gene elicited a significantly stronger antitumor immune response than the single-modified tumor cell vaccines (expressing either P1A35-43-linked beta2m or CD80 alone).
  • These findings support the feasibility and effectiveness of developing a dual-modified tumor cell vaccine consisting of the epitope-linked beta2m molecule and a co-stimulatory molecule.
  • [MeSH-major] Antigens, CD80 / immunology. Antigens, Neoplasm / immunology. Cancer Vaccines / therapeutic use. Mastocytoma / immunology. Mastocytoma / therapy. beta 2-Microglobulin / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787242.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Recombinant Fusion Proteins; 0 / beta 2-Microglobulin; 0 / tumor rejection antigen P815A, mouse; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


40. Maltby S, Khazaie K, McNagny KM: Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta; 2009 Aug;1796(1):19-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.
  • There is a growing acceptance that tumor-infiltrating myeloid cells play an active role in tumor growth and mast cells are one of the earliest cell types to infiltrate developing tumors.
  • Mast cells accumulate at the boundary between healthy tissues and malignancies and are often found in close association with blood vessels within the tumor microenvironment.
  • They express many pro-angiogenic compounds, and may play an early role in angiogenesis within developing tumors.
  • Mast cells also remodel extracellular matrix during wound healing, and this function is subverted in tumor growth, promoting tumor spread and metastasis.
  • In addition, mast cells modulate immune responses by dampening immune rejection or directing immune cell recruitment, depending on local stimuli.
  • In this review, we focus on key roles for mast cells in angiogenesis, tissue remodelling and immune modulation and highlight recent findings on the integral role that mast cells play in tumor growth.
  • New findings suggest that mast cells may serve as a novel therapeutic target for cancer treatment and that inhibiting mast cell function may lead to tumor regression.

  • MedlinePlus Health Information. consumer health - Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19977-82 [18077429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20478-83 [18077323.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4885-91 [18354212.001]
  • [Cites] EMBO J. 2008 Jun 18;27(12):1671-81 [18511911.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1269-79 [18524989.001]
  • [Cites] Cancer Lett. 2008 Sep 28;269(1):1-6 [18450371.001]
  • [Cites] Clin Exp Allergy. 2008 Aug;38(8):1254-63 [18727793.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Nov;68(2):115-30 [18632284.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] J Immunol. 2009 Jan 1;182(1):647-56 [19109198.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Jul;24(7):1265-75 [17645466.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1053-74 [10582339.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):200-3; discussion 203-4 [10759793.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):243-8 [10782883.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1020-8 [11007043.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6757-62 [11118063.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 2):323-34 [11148134.001]
  • [Cites] Clin Exp Allergy. 2001 Apr;31(4):602-8 [11359429.001]
  • [Cites] J Comp Pathol. 2001 Jul;125(1):76-9 [11437520.001]
  • [Cites] J Exp Med. 2001 Nov 5;194(9):1243-52 [11696590.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):514-21 [11736931.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2255-63 [11859113.001]
  • [Cites] Int J Hematol. 2002 May;75(4):350-6 [12041663.001]
  • [Cites] APMIS. 2002 May;110(5):355-71 [12076253.001]
  • [Cites] Methods. 2002 Sep;28(1):79-89 [12231191.001]
  • [Cites] Methods. 2002 Sep;28(1):90-6 [12231192.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):122-4 [12358914.001]
  • [Cites] Exp Hematol. 2002 Oct;30(10):1211-8 [12384153.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):387-93 [12566422.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Mar;130(3):216-23 [12660426.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):647-52 [12866022.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):195-205 [12895603.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):535-6 [12932387.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):197-201 [12949794.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1199-205 [14595438.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):690-5 [15044916.001]
  • [Cites] Br J Dermatol. 1979 Jun;100(6):623-33 [465310.001]
  • [Cites] Nature. 1982 May 20;297(5863):229-31 [6176873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 3;102(18):6467-72 [15840716.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4308-13 [15705791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11408-13 [16006518.001]
  • [Cites] Chem Immunol Allergy. 2005;87:130-44 [16107768.001]
  • [Cites] Methods Mol Biol. 2006;315:105-12 [16110152.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2360-2 [16224482.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8959-67 [16219934.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):149-59 [16258517.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2238-48 [16455980.001]
  • [Cites] Photochem Photobiol Sci. 2006 Feb;5(2):177-83 [16465303.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4102-12 [16547246.001]
  • [Cites] J Leukoc Biol. 2006 Jun;79(6):1131-9 [16617160.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1755-62 [16849485.001]
  • [Cites] Cancer Res. 1983 Dec;43(12 Pt 1):5857-61 [6640537.001]
  • [Cites] J Exp Med. 1985 Sep 1;162(3):1025-43 [3897446.001]
  • [Cites] J Immunol. 1986 Sep 15;137(6):2009-13 [3745920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(17):6485-8 [3462707.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52(3):195-206 [2432725.001]
  • [Cites] Int J Cancer. 1988 Jul 15;42(1):48-52 [2455691.001]
  • [Cites] Hum Pathol. 1989 Feb;20(2):159-63 [2562788.001]
  • [Cites] Int J Microcirc Clin Exp. 1988 Nov;7(4):315-26 [2464553.001]
  • [Cites] J Submicrosc Cytol Pathol. 1989 Jan;21(1):1-34 [2702606.001]
  • [Cites] Lab Invest. 1990 Jan;62(1):5-33 [2404155.001]
  • [Cites] Circ Res. 1990 Feb;66(2):511-6 [2137040.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):349-54 [1503910.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):785-8 [8317912.001]
  • [Cites] Dermatol Clin. 1993 Oct;11(4):685-96 [8222352.001]
  • [Cites] J Exp Med. 1994 Aug 1;180(2):471-6 [8046327.001]
  • [Cites] Immunity. 1995 Aug;3(2):175-86 [7648391.001]
  • [Cites] Chem Immunol. 1995;62:239-57 [7546284.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Clin Exp Allergy. 1995 Jul;25 Suppl 1:31-3 [8542460.001]
  • [Cites] Clin Exp Allergy. 1996 Jun;26 Suppl 4:5-7 [8809432.001]
  • [Cites] Chem Biol. 1996 Nov;3(11):895-904 [8939708.001]
  • [Cites] EXS. 1997;79:233-69 [9002222.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7151-8 [9054410.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1443-55 [9094999.001]
  • [Cites] Int Arch Allergy Immunol. 1998 Jan;115(1):47-54 [9430495.001]
  • [Cites] Mol Biol Cell. 1998 Apr;9(4):875-84 [9529385.001]
  • [Cites] Int Arch Allergy Immunol. 1998 Sep;117 Suppl 1:48-51 [9758897.001]
  • [Cites] Gut. 1999 May;44(5):643-52 [10205200.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5528-35 [10228034.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1496-503 [10359103.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Photochem Photobiol. 1999 Aug;70(2):248-53 [10461464.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2390-5 [10498611.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1317-25 [15520864.001]
  • [Cites] Circulation. 1959 Jan;19(1):87-91 [13619025.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1660-4 [15544587.001]
  • [Cites] Arthritis Res Ther. 2005;7(1):1-11 [15642148.001]
  • [Cites] Immunity. 2005 Jan;22(1):43-57 [15664158.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1588-94 [16670268.001]
  • [Cites] Nature. 2006 Aug 31;442(7106):997-1002 [16921386.001]
  • [Cites] Curr Opin Immunol. 2006 Dec;18(6):751-60 [17011762.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4222-9 [17371978.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):467-75 [17369830.001]
  • [Cites] Immunol Rev. 2007 Jun;217:5-7 [17498047.001]
  • [Cites] Immunol Rev. 2007 Jun;217:155-67 [17498058.001]
  • [Cites] Immunol Rev. 2007 Jun;217:304-28 [17498068.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2005-12 [17557898.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1211-8 [17906636.001]
  • [Cites] BMC Cancer. 2007;7:165 [17727696.001]
  • (PMID = 19233249.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104547-05; United States / NCI NIH HHS / CA / R01 CA104547; United States / NCI NIH HHS / CA / R01 CA104547-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 105
  • [Other-IDs] NLM/ NIHMS97367; NLM/ PMC2731828
  •  go-up   go-down


41. Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal KP, Garcia AP, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Gieger TL: Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. J Vet Diagn Invest; 2005 Nov;17(6):561-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference.
  • Ten veterinary pathologists independently assigned histologic grades to the same 60 canine cutaneous mast cell tumors using the Patnaik classifications.
  • Mean agreement improved significantly from 50.3% to 62.1% with uniform use of the Patnaik classifications (P = 0.00001), suggesting that there is value in uniform application of a single grading scheme for canine cutaneous mast cell tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475514.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Lamm CG, Stern AW, Smith AJ, Cooper EJ, Ullom SW, Campbell GA: Disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat. J Vet Diagn Invest; 2009 Sep;21(5):710-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat.
  • A biopsy of 1 of the lesions was submitted to the Oklahoma Animal Disease Diagnostic Laboratory for evaluation.
  • Histologically, there were multiple dermal nodules composed of sheets of neoplastic round cells.
  • Multifocally, the neoplastic cells formed multiple small clusters of 3 to 5 cells within the epidermis.
  • Distinct cytoplasmic granules were evident within the neoplastic cells with toluidine blue and Giemsa stains.
  • The neoplastic cells were immunoreactive for c-KIT and lacked immunoreactivity for cluster of differentiation 3 with immunohistochemistry.
  • Based on these findings, multiple epitheliotropic cutaneous mast cell tumors were diagnosed.
  • A complete necropsy revealed sheets of similar neoplastic mast cells within the spleen, liver, and individual cells scattered within the bone marrow.
  • To the authors' knowledge, the present report is the first to describe disseminated cutaneous mast cell tumors with epitheliotropism and systemic mastocytosis in a domestic cat.
  • [MeSH-minor] Animals. Anti-Bacterial Agents / therapeutic use. Cats. Exons. Female. Fetus. Mast Cells / pathology. Mycoses / drug therapy. Mycoses / veterinary. Prednisone / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / genetics. Skin Diseases / drug therapy. Skin Diseases / microbiology. Skin Diseases / pathology. Skin Diseases / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737771.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; VB0R961HZT / Prednisone
  •  go-up   go-down


43. Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C: The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol; 2008 Oct;36(10):1266-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
  • The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.
  • MATERIALS AND METHODS: BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.
  • STA-9090 activity was tested in a canine mastocytoma xenograft model.
  • RESULTS: Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).
  • Loss of Kit cell-surface expression was also observed.
  • Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.
  • Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.
  • CONCLUSIONS: STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clinical setting against mast cell malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 1999 Apr;27(4):689-97 [10210327.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Dec 15;114(3-4):320-34 [17027994.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1115; author reply 1115 [15705916.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1078-87 [15718306.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 [15841378.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1198-206 [15902298.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2506-12 [15972449.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3312-8 [10955818.001]
  • [Cites] Br J Haematol. 2002 Mar;116(4):744-57 [11886377.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S55-61 [11927289.001]
  • [Cites] Blood. 2002 Jul 15;100(2):585-93 [12091352.001]
  • [Cites] Am J Vet Res. 2002 Sep;63(9):1257-61 [12224856.001]
  • [Cites] Leuk Res. 2002 Nov;26(11):979-84 [12363464.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2755-68 [12855656.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):407-10 [14508491.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5):709-16 [14571418.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5729-34 [14654558.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1078-84 [14551138.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3222-5 [15070706.001]
  • [Cites] Trends Mol Med. 2004 Feb;10(2):47-51 [15106614.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4309-18 [15205346.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2004;151:1-44 [14740253.001]
  • [Cites] Anticancer Drugs. 2004 Aug;15(7):651-62 [15269596.001]
  • [Cites] J Comp Pathol. 1996 Nov;115(4):399-414 [9004081.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):761-72 [16175177.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13 [16129412.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15 [16226710.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Leuk Res. 2006 May;30(5):575-82 [16213582.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):104-11 [16611403.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1197-208 [16731752.001]
  • [Cites] Blood. 2006 Jul 1;108(1):286-91 [16434489.001]
  • [Cites] Vet Immunol Immunopathol. 2006 Sep 15;113(1-2):37-52 [16780961.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):345-51 [16779792.001]
  • [Cites] Nat Biotechnol. 2006 Nov;24(11):1307 [17093460.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6826-35 [17121904.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):3-7 [17208434.001]
  • [Cites] Nat Struct Mol Biol. 2007 Feb;14(2):90-4 [17277798.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1775-82 [17363532.001]
  • [Cites] Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S30-4 [17419150.001]
  • [Cites] Nat Chem Biol. 2007 Aug;3(8):498-507 [17603540.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):303 [17351742.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):543-6 [16832603.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1369-78 [16923571.001]
  • [Cites] Gastric Cancer. 2006;9(3):235-9 [16952044.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9153-61 [16982758.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):838-9 [10468886.001]
  • (PMID = 18657349.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093807; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCATS NIH HHS / TR / UL1 TR000090; United States / NCI NIH HHS / CA / R01 CA93807
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / HSP90 Heat-Shock Proteins; 0 / STA 9090; 0 / Triazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ NIHMS522755; NLM/ PMC3837096
  •  go-up   go-down


44. Martínez-Lage JF, Niguez BF, Pérez-Espejo MA, Almagro MJ, Maeztu C: Midline cutaneous lumbosacral lesions: not always a sign of occult spinal dysraphism. Childs Nerv Syst; 2006 Jun;22(6):623-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The pathological diagnosis of the masses was plexiform neurofibroma and mastocytoma, respectively.
  • Plexiform neurofibroma and skin mastocytoma are very rare indeed in this spinal location.
  • CONCLUSION: The two cases represent an important addition to the differential diagnosis of a congenital dorsal midline mass.
  • [MeSH-major] Mastocytoma / diagnosis. Neurofibroma / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Lumbosacral Region. Magnetic Resonance Imaging / methods. Male. Spinal Dysraphism / diagnosis

  • Genetic Alliance. consumer health - Occult spinal dysraphism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16453111.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Grabarević Z, Spoljar JB, Kurilj AG, Sostarić-Zuckermann IC, Artuković B, Hohsteter M, Beck A, Dzaja P, Strmecki NM: Mast cell tumor in dogs--incidence and histopathological characterization. Coll Antropol; 2009 Mar;33(1):253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tumor in dogs--incidence and histopathological characterization.
  • Incidence of mast cell tumors, their distribution according to sex, breed, age and localisation in Croatia is not established yet.
  • Also, the statistical significance of the various histopathological parameters according to Patnaik's scheme, in the diagnostics of the tumor grade was not performed.
  • Investigation analysed mast cell tumors histopathologicaly characterized at the Department of General Pathology and Pathological Morphology of the Veterinary Faculty Zagreb from January 1st 2002 to December 31st 2006.
  • Sex, age, breed, localisation and tumor grade of each animal with tumor was recorded and statisticaly evaluated.
  • Each histopathological variable was scored and compared with tumor grade.
  • In the analyzed period, totally 1630 tumors were recorded, and mast cell tumors were found in 106 animals or in 6.5% of all cases.
  • With statistically significant difference, this tumor was found in more cases in male dogs, and average age was 6.96 years.
  • Grade I tumor was found in 15.09%, grade II in 44.34% and grade III in 28.3% of animals.
  • There were no significant correlations between tumor grade and age, breed, sex or localization.
  • Considering the lesion scores compared with grade, statistically significant differences were found in cell shape, number of nucleoli, anisocytosis, anisokariosis, karyomegaly, mitoses, necroses, hemorrhages, cellularity, cell borders and collagenolysis.
  • [MeSH-major] Dog Diseases / pathology. Mastocytoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408634.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  •  go-up   go-down


46. Taney K, Smith MM: Resection of mast cell tumor of the lip in a dog. J Vet Dent; 2009;26(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of mast cell tumor of the lip in a dog.
  • A 10-year-old Boston terrier dog was presented for treatment of a 2-cm mast cell tumor of the left upper lip and nasal planum immediately adjacent to the philtrum and ventral to the nares.
  • [MeSH-major] Dog Diseases / surgery. Lip Neoplasms / veterinary. Mast-Cell Sarcoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Vet Dent. 2009 Summer;26(2):120
  • (PMID = 19476085.001).
  • [ISSN] 0898-7564
  • [Journal-full-title] Journal of veterinary dentistry
  • [ISO-abbreviation] J Vet Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL: Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Vet Comp Oncol; 2010 Sep;8(3):209-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
  • Calcitriol potentiates the effect of multiple chemotherapy agents in a variety of tumour models.
  • In this study, we examine whether calcitriol increases chemotherapy or tyrosine kinase inhibitor in vitro cytotoxicity in canine mastocytoma C2 cells.
  • We also evaluate the in vivo effect of DN101, a highly concentrated oral formulation of calcitriol designed specifically for cancer therapy, as a single-agent therapy in dogs with mast cell tumours (MCTs).
  • [MeSH-major] Calcitriol / therapeutic use. Calcium Channel Agonists / therapeutic use. Dog Diseases / drug therapy. Mastocytoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Benzamides. Blotting, Western / veterinary. Cell Line, Tumor. Dogs. Dose-Response Relationship, Drug. Drug Synergism. Female. Imatinib Mesylate. Indoles / pharmacology. Lomustine / pharmacology. Male. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / pharmacology. Pyrroles / pharmacology. Receptors, Calcitriol / analysis. Treatment Outcome. Vinblastine / pharmacology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20691028.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067267; United States / NCI NIH HHS / CA / R01 CA095045
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Calcium Channel Agonists; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / Receptors, Calcitriol; 24F9PF7J3R / toceranib phosphate; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; FXC9231JVH / Calcitriol
  •  go-up   go-down


48. Lin TY, Hamberg A, Pentecost R, Wellman M, Stromberg P: Mast cell tumors in a llama (Lama glama). J Vet Diagn Invest; 2010 Sep;22(5):808-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tumors in a llama (Lama glama).
  • Cytological evaluation of fine-needle aspirates from the cutaneous mass from the left shoulder and right hip comprised many well-differentiated, highly granulated mast cells with moderate numbers of eosinophils.
  • Occasional mast cells exhibited erythrophagocytosis and contained a small amount of hemosiderin or several variably sized vacuoles.
  • A cytologic diagnosis of mast cell tumor with evidence of prior hemorrhage was made, and the masses were surgically removed.
  • Microscopically, each mass consisted of sheets of neoplastic round cells that formed nonencapsulated nodules in the dermis and infiltrated into the adjacent dermal collagen.
  • Eosinophils were scattered among the mast cells at the periphery of the nodules.
  • Neoplastic mast cells, but not eosinophils, exhibited positive membrane KIT expression and cytoplasmic vimentin staining.
  • A final diagnosis of mast cell tumor was made based on cytology, histology, and immunohistochemistry.
  • [MeSH-major] Camelids, New World / blood. Mastocytoma / veterinary
  • [MeSH-minor] Animals. Biopsy, Fine-Needle / methods. Biopsy, Fine-Needle / veterinary. Blood Donors. Cytoplasmic Granules / pathology. Dog Diseases / pathology. Dogs. Female. Humans. Mutation. Neoplasm Metastasis. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Skin Neoplasms / veterinary. Species Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807950.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kobie K, Kawabata M, Hioki K, Tanaka A, Matsuda H, Mori T, Maruo K: The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Res Vet Sci; 2007 Apr;82(2):239-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
  • Canine mast cell tumors (MCTs) are the most common cutaneous tumors in the dog.
  • They have a wide range of behaviour, which can make these tumors challenging to treat.
  • Imatinib is the first member of a new class of agents that act by inhibiting particular tyrosin kinase enzymes, including KIT which is a product of the c-kit.
  • Significant tumor regression occurred with 100mg/kg on days 7, 10, 14 and 21, and 200mg/kg on all days.
  • Our results indicate that imatinib is effective against canine mast cell tumor in mouse xenograft models.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Dog Diseases / drug therapy. Mast-Cell Sarcoma / drug therapy. Mast-Cell Sarcoma / veterinary. Piperazines / pharmacology. Pyrimidines / pharmacology. Skin Neoplasms / drug therapy. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919303.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


50. He XJ, Uchida K, Tochitani T, Uetsuka K, Miwa Y, Nakayama H: Spontaneous cutaneous mast cell tumor with lymph node metastasis in a Richardson's ground squirrel (Spermophilus richardsonii). J Vet Diagn Invest; 2009 Jan;21(1):156-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous cutaneous mast cell tumor with lymph node metastasis in a Richardson's ground squirrel (Spermophilus richardsonii).
  • Histologically, the nodules were composed of a proliferation of spindloid to pleomorphic cells that sometimes formed sheets and fascicular to storiform patterns.
  • The results of immunohistochemistry indicated positive labeling for vimentin, mast cell tryptase, c-kit, and Ki-67.
  • The histologic diagnosis was mast cell tumor.
  • The neoplasm recurred and metastasized to the right lumbar lymph node 1 month later.
  • [MeSH-major] Lymphoma / veterinary. Mastocytoma, Skin / veterinary. Rodent Diseases / pathology. Sciuridae

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139521.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Alsharqi A, Parslew R, Shukla R: A 3-month-old with a blistering plaque. Dermatol Online J; 2010;16(9):10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 3-month-old child with a solitary mastocytoma who was initially diagnosed with recurrent bullous impetigo.
  • Solitary mastocytoma can present as a blister.
  • Although bullous impetigo is a common diagnosis in children and it would be tempting to make that diagnosis in the presence of a positive skin swab culture, clinicians always have to be mindful of secondary impetiginization of another primary skin disease process.
  • [MeSH-major] Mastocytoma, Skin / diagnosis
  • [MeSH-minor] Blister / etiology. Diagnosis, Differential. Erythema / etiology. Female. Humans. Impetigo / etiology. Infant. Leg / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20875331.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ohashi E, Miyajima N, Nakagawa T, Takahashi T, Kagechika H, Mochizuki M, Nishimura R, Sasaki N: Retinoids induce growth inhibition and apoptosis in mast cell tumor cell lines. J Vet Med Sci; 2006 Aug;68(8):797-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoids induce growth inhibition and apoptosis in mast cell tumor cell lines.
  • To investigate the antitumor effect of retinoids on mast cell tumors (MCT), inhibitory effect on cell growth and induction of apoptosis were examined in vitro.
  • Although sensitivity of these cells differed among the cells, the growth of three MCT cell lines (CoMS, CM-MC and VI-MC) were inhibited dose dependently when they were treated with retinoids.
  • FACS analysis of PI-stained nuclei revealed an apoptotic fraction in CM-MC cells about 30% when treated with retinoids, while those of control cells were less than 5%.
  • Caspase-3 activation was observed after retinoid treatment in CM-MC cells.
  • Both retinoid receptors, RARs and RXRs, were detected by immunoprecipitation followed by western blot analysis in all the three MCT cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16953078.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Retinoids; EC 3.4.22.- / Caspases
  •  go-up   go-down


53. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M: Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med; 2008 Jul-Aug;22(4):985-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
  • Mutation of c-kit exon 11, which induces constitutive phosphorylation of KIT, is one of the mechanisms for the development or progression of mast cell tumor (MCT) in dogs.
  • HYPOTHESIS: Imatinib mesylate has activity against MCT in dogs, and response to treatment can be correlated to presence of mutation within exon 11 of c-kit.
  • ANIMALS: Twenty-one dogs with MCT with gross tumor burden and median tumor size of 7.2 cm (range, 1.0-25.3 cm) before treatment.
  • METHODS: Tumors were analyzed for mutation of c-kit exon 11.
  • Response could not be predicted based on presence of absence of a mutation in exon 11 of c-kit.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564222.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


54. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM: Activation and function of the mTORC1 pathway in mast cells. J Immunol; 2008 Apr 1;180(7):4586-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation and function of the mTORC1 pathway in mast cells.
  • Little is known about the signals downstream of PI3K which regulate mast cell homeostasis and function following FcepsilonRI aggregation and Kit ligation.
  • In human and mouse mast cells, stimulation via FcepsilonRI or Kit resulted in a marked PI3K-dependent activation of the mTORC1 pathway, as revealed by the wortmannin-sensitive sequential phosphorylation of tuberin, mTOR, p70S6 kinase (p70S6K), and 4E-BP1.
  • In contrast, in human tumor mast cells, the mTORC1 pathway was constitutively activated and this was associated with markedly elevated levels of mTORC1 pathway components.
  • In parallel, although rapamycin had no effect on FcepsilonRI-mediated degranulation or Kit-mediated cell adhesion, it inhibited cytokine production, and kit-mediated chemotaxis and cell survival.
  • Furthermore, Rapamycin also blocked the constitutive activation of the mTORC1 pathway and inhibited cell survival of tumor mast cells.
  • These data provide evidence that mTORC1 is a point of divergency for the PI3K-regulated downstream events of FcepsilonRI and Kit for the selective regulation of mast cell functions.
  • Specifically, the mTORC1 pathway may play a critical role in normal and dysregulated control of mast cell homeostasis.
  • [MeSH-major] Mast Cells / immunology. Mast Cells / metabolism. Signal Transduction / immunology. Transcription Factors / immunology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Cell Survival. Cells, Cultured. Humans. Kinetics. Mice. Multiprotein Complexes. Neoplasms / metabolism. Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism. Proteins. Proto-Oncogene Proteins c-kit / metabolism. Receptors, IgE / immunology. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1053-74 [10582339.001]
  • [Cites] Novartis Found Symp. 2005;271:152-61; discussion 161-5, 198-9 [16605133.001]
  • [Cites] Nature. 2001 Jul 12;412(6843):186-90 [11449275.001]
  • [Cites] Immunity. 2002 Mar;16(3):441-51 [11911828.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4871-80 [11994436.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Cell. 2002 Jul 26;110(2):177-89 [12150926.001]
  • [Cites] J Immunol Methods. 2002 Oct 15;268(2):239-43 [12215392.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):773-86 [12360215.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jun;117(6):1214-25; quiz 1226 [16750977.001]
  • [Cites] Immunol Res. 2006;34(2):97-115 [16760571.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1065-72 [16597595.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2366-72 [16741248.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6373-83 [17041623.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):859-71 [17141160.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):93-103 [17190838.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):93-104 [17259966.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4177-83 [17371974.001]
  • [Cites] Trends Immunol. 2007 May;28(5):234-41 [17400512.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4412-9 [12907613.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):524-35 [12928787.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48474-84 [13129935.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7254-62 [15187100.001]
  • [Cites] Blood. 2004 Jul 1;104(1):207-14 [15010370.001]
  • [Cites] Arerugi. 2004 Jun;53(6):557-61 [15247516.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6710-8 [15254238.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):1296-302 [15268862.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2410-7 [15217825.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9508-16 [15485918.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):1007-11 [15496927.001]
  • [Cites] J Immunol Methods. 1986 May 22;89(2):271-7 [3486233.001]
  • [Cites] J Immunol. 1992 Feb 1;148(3):772-7 [1370517.001]
  • [Cites] J Exp Med. 1992 Jan 1;175(1):237-44 [1370529.001]
  • [Cites] Eur J Immunol. 1993 Dec;23(12):3286-91 [7504992.001]
  • [Cites] Scand J Immunol. 1994 May;39(5):489-98 [8191224.001]
  • [Cites] J Immunol. 1994 Oct 15;153(8):3717-23 [7523504.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1942-5 [8596048.001]
  • [Cites] Mol Biol Cell. 1997 May;8(5):909-22 [9168474.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2333-42 [10498605.001]
  • [Cites] Trends Mol Med. 2005 Aug;11(8):353-61 [16002336.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Nat Rev Immunol. 2006 Mar;6(3):218-30 [16470226.001]
  • [Cites] FASEB J. 2006 Mar;20(3):455-65 [16507763.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):729-40 [10974038.001]
  • (PMID = 18354181.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI000965-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / Proteins; 0 / Receptors, IgE; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS112335; NLM/ PMC2698706
  •  go-up   go-down


55. Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael J: Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res; 2007 Nov;68(11):1246-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
  • OBJECTIVE: To evaluate safety and efficacy of LDI-100, a preparation containing human chorionic gonadotropin (hCG) and bacillus Calmette-Guerin (BCG), in the treatment of dogs with mast cell tumors and to compare results with those from a control group receiving single-agent vinblastine.
  • ANIMALS: 95 dogs with measurable grade II or III mast cell tumors.
  • Tumors were measured at baseline and day 42, and dogs were monitored for signs of toxicosis.
  • Differences in host factors (sex, weight, and age), clinical performance score, tumor response, and adverse events were analyzed.
  • Tumor response (>or=50% reduction) rates were similar between the LDI-100 and vinblastine group (28.6% and 11.7%, respectively).
  • LDI-100 is a promising new agent that should be further investigated for multimodality therapy of mast cell tumors in dogs.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Chorionic Gonadotropin / therapeutic use. Dog Diseases / therapy. Mastocytoma / veterinary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975981.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 0 / Chorionic Gonadotropin; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


56. Seeliger F, Hess O, Pröpsting MJ, Naim HY, Kleinschmidt S, Woehrmann T, Germann PG, Baumgärtner W: Confocal laser scanning analysis of an equine oral mast cell tumor with atypical expression of tyrosine kinase receptor C-KIT. Vet Pathol; 2007 Mar;44(2):225-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser scanning analysis of an equine oral mast cell tumor with atypical expression of tyrosine kinase receptor C-KIT.
  • A 20-year-old female horse showed a nodular, firm, focal ulcerated mast cell tumor at the right dorsobuccal face of the tongue.
  • Histologically, the nonencapsulated tumor consisted of dense, infiltrating aggregates of well-differentiated, Cresyl violet-positive mast cells accompanied by numerous eosinophils.
  • Confocal laser scanning microscopy confirmed an aberrant spatial colocalization of KIT in the Golgi apparatus, which may be the result of a defective protein processing within the tumor cells.
  • The tumor was not associated with a poor prognosis.
  • [MeSH-major] Horse Diseases / enzymology. Horse Diseases / pathology. Mastocytoma / veterinary. Proto-Oncogene Proteins c-kit / biosynthesis. Tongue Neoplasms / enzymology. Tongue Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Vet Pathol. 2007 May;44(3):427. Pröbsting, M [corrected to Pröpsting, M J]; Naim, H Y [added]
  • (PMID = 17317803.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


57. Matsuda K, Sakaguchi K, Kobayashi S, Tominaga M, Hirayama K, Kadosawa T, Taniyama H: Systemic candidiasis and mesenteric mast cell tumor with multiple metastases in a dog. J Vet Med Sci; 2009 Feb;71(2):229-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic candidiasis and mesenteric mast cell tumor with multiple metastases in a dog.
  • A 5-year-old female miniature dachshund presenting with persistent vomiting and diarrhea had two concurrent rare pathological conditions: systemic candidiasis and mesenteric mast cell tumor with multiorgan metastases.
  • Neoplastic mast cells formed mass in the mesentery of the cecal-colonic region and were also found in the liver, spleen, kidneys, lungs, adrenal grands, ovaries, bone marrow and other tissues.
  • The cells had intracytoplasmic granules with metachromasia and were immunohistochemically positive for c-kit and histamine.

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262039.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


58. Seledtsov VI, Seledtsova GV, Samarin DM, Senyukov VV, Poveschenko OV, Felde MA, Kozlov VA: Erythroid cells in suppressing leukemia cell growth. Leuk Lymphoma; 2005 Sep;46(9):1353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythroid cells in suppressing leukemia cell growth.
  • This paper indicates that murine nucleated erythroid cells (EC) are able to reduce, in a dose-dependent manner, the proliferation of both L1210 lymphoma and P815 mastocytoma cells and that the leukemia cell growth inhibitory activity of unseparated bone marrow (BM) cells may be markedly augmented by their short-term culturing with erythropoietin (Epo).
  • These results raise the intriguing possibility to utilize erythropoesis-stimulating, therapeutic strategies with the purpose of inhibiting leukemia cell growth in the body.
  • [MeSH-major] Erythroid Cells / cytology. Leukemia, Experimental / pathology
  • [MeSH-minor] Animals. Bone Marrow Cells / physiology. Cell Division / drug effects. Cells, Cultured. Erythropoietin / pharmacology. Leukemia L1210 / pathology. Mice. Mice, Inbred Strains. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109614.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin
  •  go-up   go-down


59. Millward LM, Hamberg A, Mathews J, Machado-Parrula C, Premanandan C, Hurcombe SD, Radin MJ, Wellman ML: Multicentric mast cell tumors in a horse. Vet Clin Pathol; 2010 Sep;39(3):365-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric mast cell tumors in a horse.
  • Direct smears of fluid collected by fine-needle aspiration of subcutaneous fluid from both limbs were highly cellular with a predominance of eosinophils accompanied by numerous, moderately atypical, variably granulated mast cells.
  • The cytologic diagnosis was mast cell tumor (MCT) with prominent eosinophilic infiltration with a differential diagnosis of eosinophilic granuloma.
  • The histologic diagnosis was MCT, and staining with toluidine blue and Luna stains confirmed the presence of mast cells and eosinophils, respectively.
  • In addition, the mast cells strongly expressed CD117.
  • This is the first reported case of cutaneous mast cell neoplasia in a horse in which primary presenting complaints were draining tracts and distal limb subcutaneous edema involving multiple limbs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 American Society for Veterinary Clinical Pathology.
  • (PMID = 20412546.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Mojahidi S, Rakib el M, Sekkak H, Abouricha S, Benchat N, Mousse HA, Zyad A: Synthesis and in-vitro cytotoxic evaluation of novel pyridazin-4-one derivatives. Arch Pharm (Weinheim); 2010 May;343(5):310-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of these compounds exhibited in-vitro cytotoxic activity with moderate to excellent growth inhibition against the murine P815 mastocytoma cell line.
  • Compound 5b showed an important cytotoxic activity against cell line P815 (IC(50 )= 0.40 microg/mL).
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Pyridazines / chemical synthesis. Pyridazines / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor / methods. Mice. Molecular Structure. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222064.001).
  • [ISSN] 1521-4184
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyridazines
  •  go-up   go-down


61. Schmidt CS, Bentz ML: Congenital smooth muscle hamartoma: the importance of differentiation from melanocytic nevi. J Craniofac Surg; 2005 Sep;16(5):926-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical differential diagnosis of CSMH includes congenital melanocytic (pigmented) nevus, Becker's melanosis, solitary mastocytoma, piloleiomyoma, café-au-lait spots, and nevus pilosus.
  • [MeSH-minor] Cafe-au-Lait Spots / diagnosis. Diagnosis, Differential. Humans. Infant. Leiomyoma / diagnosis. Male. Mastocytoma / diagnosis. Melanosis / diagnosis. Nevus / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192884.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Bulat V, Mihić LL, Situm M, Buljan M, Blajić I, Pusić J: Most common clinical presentations of cutaneous mastocytosis. Acta Clin Croat; 2009 Mar;48(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term mastocytosis is referred to as an array of uncommon, usually sporadic, heterogeneous clinical illnesses that result from the hyperplasia of tissue mast cells.
  • The characteristic presentation of mastocytosis consists of cutaneous manifestations: either a solitary mastocytoma, urticaria pigmentosa, or less commonly, diffuse cutaneous mastocytosis.
  • Mastocytosis may also be manifested as mastocytoma, a rare, benign, pediatric tumor that results from hyperplasia of mast cells in papillary dermis in the first few weeks of life.
  • The prognosis for the majority of pediatric patients with urticaria pigmentosa is extremely good, and over half of cases clear completely by adolescence, while those with aggressive systemic mastocytosis or mast cell leukemia show a progressive course, usually with a fatal outcome.
  • [MeSH-major] Mastocytosis, Cutaneous / diagnosis

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623875.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 17
  •  go-up   go-down


63. Akoglu G, Erkin G, Cakir B, Boztepe G, Sahin S, Karaduman A, Atakan N, Akan T, Kolemen F: Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):969-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mastocytosis is a rare, heterogeneous group of disorder with abnormal increase of mast cells in one or more organ systems.
  • RESULTS: Of the 22 females and 33 males, 80% had urticaria pigmentosa/maculopapular CM and 20% had mastocytoma.
  • CONCLUSION: Clinical presentations of urticaria pigmentosa/maculopapular CM and mastocytoma are similar regarding gender, age of onset, age of diagnosis, and presence of Darier's sign and history of bulla.
  • In contrast to mastocytoma, urticaria pigmentosa/maculopapular CM lesions were frequently located on trunk together with extremities.

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922947.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Krop M, van Veghel R, Garrelds IM, de Bruin RJ, van Gool JM, van den Meiracker AH, Thio M, van Daele PL, Danser AH: Cardiac Renin levels are not influenced by the amount of resident mast cells. Hypertension; 2009 Aug;54(2):315-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac Renin levels are not influenced by the amount of resident mast cells.
  • To investigate whether mast cells release renin in the heart, we studied renin and prorenin synthesis by such cells, using the human mast cell lines human mastocytoma 1 and LAD2, as well as fresh mast cells from mastocytosis patients.
  • We also quantified the contribution of mast cells to cardiac renin levels in control and infarcted rat hearts.
  • Human mastocytoma 1 cells contained and released angiotensin I-generating activity, and the inhibition of this activity by the renin inhibitor aliskiren was comparable to that of recombinant human renin.
  • Angiotensin I-generating activity was undetectable in LAD2 cells and fresh mast cells.
  • Results in infarcted hearts were identical, despite the increased mast cell number in such hearts.
  • In conclusion, human mastocytoma 1 cells release renin and prorenin, and the regulation of this release resembles that of renal renin.
  • However, this is not a uniform property of all mast cells.
  • Mast cells appear an unlikely source of renin in the heart, both under normal and pathophysiological conditions.
  • [MeSH-major] Mast Cells / metabolism. Myocardium / metabolism. Renin / metabolism. Renin-Angiotensin System / physiology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Angiotensin I / pharmacology. Animals. Cells, Cultured. Disease Models, Animal. Female. Humans. Male. Myocytes, Cardiac / metabolism. Probability. Random Allocation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564544.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9041-90-1 / Angiotensin I; EC 3.4.23.15 / Renin
  •  go-up   go-down


65. Baldi A, Colloca E, Spugnini EP: Lomustine for the treatment of gastrointestinal mast cell tumour in a dog. J Small Anim Pract; 2006 Aug;47(8):465-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lomustine for the treatment of gastrointestinal mast cell tumour in a dog.
  • An eight-year-old, male boxer dog was referred for the treatment of a large (5.5 x 5 cm), unresectable visceral mast cell tumour.
  • The patient was treated with lomustine and prednisone and showed a rapid improvement and increased level of activity, weight gain and consistent tumour reduction.
  • The patient remained in partial remission (defined as a greater than 50 per cent reduction in tumour volume) for seven months.
  • At that time, the tumour was still in partial remission.
  • This case report suggests that a combination of lomustine and prednisone is an effective protocol for the palliation of aggressive visceral mast cell tumours.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dog Diseases / drug therapy. Gastrointestinal Neoplasms / veterinary. Lomustine / therapeutic use. Mast-Cell Sarcoma / veterinary

  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911116.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


66. Litviakov NV, Buldakov MA, Cherdyntseva NV, Rostov VV, Klimov AI, Bol'shakov MA: [Effect of impulse-intermittent ultrahigh frequency irradiation on synthesis of nucleic acids in tumor cells]. Radiats Biol Radioecol; 2005 Jul-Aug;45(4):460-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of impulse-intermittent ultrahigh frequency irradiation on synthesis of nucleic acids in tumor cells].
  • In this work is shown that the repetitive high power microwaves is able to exert an inhibitory influence on the process of DNA and RNA syntheses in tumor cells of P-815 mastocytoma.
  • High power microwave pulses inhibit the process of transcription in tumor cells.
  • No activation of DNA reparation system due to the irradiation of non-proliferating mononuclear blood cells was found.
  • This indicates that the repetitive high power microwaves are not able to initiate single-filament rupture in DNA of tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209193.001).
  • [ISSN] 0869-8031
  • [Journal-full-title] Radiatsionnaia biologiia, radioecologiia
  • [ISO-abbreviation] Radiats Biol Radioecol
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Nucleic Acids
  •  go-up   go-down


67. Masserdotti C, Bonfanti U, De Lorenzi D, Tranquillo M, Zanetti O: Cytologic features of testicular tumours in dog. J Vet Med A Physiol Pathol Clin Med; 2005 Sep;52(7):339-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of testicular tumours in dog.
  • In this paper, we report on our experience of cytology of fine needle biopsies performed on 92 dogs with testicular tumours during the period from 1998 to 2002.
  • Cytological diagnosis was consistent with seminoma in 20 cases, sertolioma in 16 cases, Leydig cell tumours in 50 cases and mastocytoma in one case.
  • Cytology provided a sensitivity of 95% for seminoma, 88% for sertolioma and 96% for Leydig cell tumours.
  • The specificity was 100% for all three tumour types.
  • In our experience cytology of fine needle aspirations of testicular tumours is a very reliable technique.
  • [MeSH-minor] Animals. Dogs. Italy / epidemiology. Leydig Cell Tumor / pathology. Leydig Cell Tumor / veterinary. Male. Mastocytoma / pathology. Mastocytoma / veterinary. Predictive Value of Tests. Seminoma / pathology. Seminoma / veterinary. Sensitivity and Specificity. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / veterinary

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109100.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Briley LD, Phillips CM: Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila); 2008 Oct;47(8):757-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous mastocytosis can be divided into 4 different clinical variants--urticaria pigmentosa, solitary mastocytoma, diffuse cutaneous mastocytosis, and telangiectasia macularis eruptiva perstans.
  • Skin findings are often accompanied by symptoms secondary to mast cell release of mediators.
  • This article will review each of the 4 clinical presentations focusing on pediatric-onset of disease while reviewing the literature.
  • [MeSH-major] Mastocytosis, Cutaneous / diagnosis. Mastocytosis, Cutaneous / therapy
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502981.001).
  • [ISSN] 0009-9228
  • [Journal-full-title] Clinical pediatrics
  • [ISO-abbreviation] Clin Pediatr (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


69. Helgason CD: Culture of primary adherent cells and a continuously growing nonadherent cell line. Methods Mol Biol; 2005;290:1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Culture of primary adherent cells and a continuously growing nonadherent cell line.
  • Cell culture is an invaluable tool for investigators in numerous fields.
  • Successful maintenance of cells in culture, whether primary or immortalized, requires knowledge and practice of a few essential techniques.
  • The purpose of this chapter is to explain the basic principles of cell culture using the maintenance of a nonadherent cell line, the P815 mouse mastocytoma cell line, and the isolation and culture of adherent primary mouse embryonic fibroblasts (MEFs) as examples.
  • Procedures for thawing, culture, determination of cell numbers and viability, and cryopreservation are described.
  • [MeSH-major] Cell Adhesion. Cell Culture Techniques / methods
  • [MeSH-minor] Animals. Cell Line. Cryopreservation. Embryo, Mammalian / cytology. Fibroblasts / cytology. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361651.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Barsotti G, Marchetti V, Abramo F: Primary conjunctival mast cell tumor in a Labrador Retriever. Vet Ophthalmol; 2007 Jan-Feb;10(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary conjunctival mast cell tumor in a Labrador Retriever.
  • A poorly differentiated mast cell tumor was diagnosed by cytology.
  • After a complete clinical staging, the mass was excised and identified histologically as a grade-II mast cell tumor.
  • This report contributes to the current literature pertaining to canine conjunctival mast cell tumors; unfortunately, the paucity of case reports and the absence of large studies regarding this tumor make conclusions regarding its biologic behavior impossible.
  • [MeSH-major] Conjunctival Neoplasms / veterinary. Dog Diseases / diagnosis. Mast-Cell Sarcoma / veterinary
  • [MeSH-minor] Animals. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Techniques, Ophthalmological / veterinary. Dogs. Male. Pedigree

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204130.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Stanclift RM, Gilson SD: Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc; 2008 Jan 1;232(1):53-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
  • OBJECTIVE: To determine response rate and reduction in tumor burden and effect of dose on tumor response in dogs treated with neoadjuvant prednisone for cutaneous mast cell tumors (MCTs).
  • Tumor characteristics and response to treatment were recorded.
  • Prospectively, the median sum maximal diameter (MaxD) reduction was 45.2%, and reduction in tumor volume was 80.6%.
  • In both treatment groups, the mean percentage MaxD reduction and tumor volume reduction were significant.
  • The LD group had mean MaxD and tumor volume reductions of 35.4% and 52.5%, respectively, compared with mean reductions of 48.8% in MaxD and 78% in tumor volume in the HD group.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Dog Diseases / drug therapy. Mast-Cell Sarcoma / veterinary. Prednisone / therapeutic use. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Combined Modality Therapy / veterinary. Disease-Free Survival. Dogs. Dose-Response Relationship, Drug. Female. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Random Allocation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167109.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; VB0R961HZT / Prednisone
  •  go-up   go-down


72. Starska K, Brzezińska-Błaszczyk E: [The role of stromal mast cells in the modification of CD4+CD25+Foxp³ regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor]. Postepy Hig Med Dosw (Online); 2010 Aug 23;64:408-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of stromal mast cells in the modification of CD4+CD25+Foxp³ regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor].
  • Despite the lack of direct evidence that immune surveillance cells protect against tumor development, indirect clinical observations and experimental studies indicate activity in the immune response against cancer cells of various origin.
  • Little is known about the effects of the stromal tumor mast cell (MC) in the activity of immune cells, i.e.
  • CD4+CD25+Foxp³+ regulatory T cells, Th17 lymphocytes, cytotoxic lymphocytes Tc1 and their mutual modulatory function and regulation of the antitumor immune response.
  • Factors synthesized by stromal tumor mast cells including histamine, COX-2, CXCL8 (IL-8), VEGF, IL-6, TNF, iNOS, MMP-8, and MMP-9 may, on the one hand, directly affect the activity of T lymphocyte subpopulations, i.e. iTreg, Tc1, and Th17, and thus regulate immunological processes occurring in the vicinity of the tumor.
  • On the other hand, through effects on angiogenesis, apoptosis, the cell cycle, secretion of cytokines and the expression of adhesion molecules, they may indirectly determine the progression of the neoplasm.
  • Understanding the regulatory mechanisms occurring in the system: tumor stroma mast cell → immune cells infiltrating the tumor (iTreg, Tc1, Th17 lymphocytes) → expression of factors involved in angiogenesis, apoptosis, the cell cycle, and secretion of cytokines and adhesion molecules creates the future possibility of influencing the activation and regulation of selected proneoplastic and antineoplastic factors appearing in the neoplasm environment.
  • Research on these mechanisms may be the beginning of a new approach to the fight against cancer growth and provide an opportunity to introduce new methods of treatment.
  • The aim of this study was to present the current knowledge on the role of stromal tumor CD117+ mast cells and factors secreted by these cells in the activation of T lymphocyte subpopulations, i.e.
  • CD4+CD25+Foxp³+ regulatory T cells, Th17 lymphocytes, and cytotoxic lymphocytes Tc1, as well as to present their impact on the degree of tumor invasiveness by regulating the synthesis of factors secreted by the lymphocyte subpopulations studied, e.g.

  • MedlinePlus Health Information. consumer health - Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966498.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


73. Neub A, Krahl D, Stich A, Amon U: Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges; 2008 Dec;6(12):1061-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A two-year-old girl presented with a 20 month history of a facial nodule which had appeared after a vacation on Mallorca.
  • Various topical treatments at other hospitals for the working diagnosis of mastocytoma failed to prevent a slow increase in size and the onset of systemic signs and symptoms.
  • [MeSH-major] Leishmania infantum / drug effects. Leishmaniasis, Visceral / diagnosis. Leishmaniasis, Visceral / drug therapy. Phosphorylcholine / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498377.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 107-73-3 / Phosphorylcholine; 53EY29W7EC / miltefosine
  •  go-up   go-down


74. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ: The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol; 2010 Dec;5(12):2024-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of inflammation in the pathogenesis of non-small cell lung cancer.
  • Compelling evidence has accumulated that histologic assessment of infiltration patterns of different host immune response components in non-small cell lung cancer specimens helps identify different prognostic patient subgroups.
  • The usefulness of quantification of different populations of lymphocytes, natural killer cells, macrophages, and mast cells within the tumor microenvironment in non-small cell lung cancer is also discussed.
  • In particular, the importance of assessment of inflammatory cell microlocalization within both the tumor islet and surrounding stromal components is emphasized.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / etiology. Inflammation / complications. Lung Neoplasms / etiology
  • [MeSH-minor] Adaptive Immunity. Animals. CD4-Positive T-Lymphocytes / immunology. Chronic Disease. Humans. Immunity, Cellular. Occupational Exposure / adverse effects. Prognosis. Pulmonary Disease, Chronic Obstructive / complications. Tobacco Smoke Pollution / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155185.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  •  go-up   go-down


75. Brown HM, Cuttino E, LeRoy BE: A subcutaneous mass on the neck of a horse. Vet Clin Pathol; 2007 Mar;36(1):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subcutaneous mass on the neck of a horse.
  • A 25-year-old Arabian gelding was presented for investigation of a subcutaneous neck mass.
  • Fine-needle aspirates and impression smears revealed mast cells with widely varying degrees of cytoplasmic granulation and scattered eosinophils.
  • Histopathology revealed a poorly circumscribed mass composed of sheets and bundles of mast cells with a large population of eosinophils.
  • The mast cells were separated into numerous lobules by a heavy collagenous stroma, and multifocal collagen necrosis was present.
  • Strong reactivity of the tumor cells for both Giemsa and toluidine blue stains confirmed the diagnosis of a mast cell tumor, and a Luna stain accentuated the eosinophilic infiltrates.
  • Cutaneous mast cell tumors are found in many domestic animals but are uncommonly encountered in horses.
  • Equine cutaneous mast cell tumors are usually benign, and there are no reports of visceral metastasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311206.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P: KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol; 2010 Sep;38(9):782-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
  • OBJECTIVE: Advanced systemic mastocytosis (SM) is characterized by uncontrolled growth of neoplastic mast cells (MC) and drug resistance.
  • MATERIALS AND METHODS: We determined the effects of the multikinase inhibitor INNO-406 (bafetinib) on primary neoplastic MC, the canine mastocytoma cell line C2, the human MC leukemia cell line HMC-1.1 bearing the KIT mutant V560G, and HMC-1.2 cells harboring KIT V560G and KIT D816V.
  • RESULTS: INNO-406 was found to inhibit proliferation in HMC-1.1 cells (IC(50): 30-40 nM), but not in HMC-1.2 cells or primary neoplastic cells in patients with KIT D816V-positive SM.
  • In canines, growth-inhibitory effects of INNO-406 were seen in C2 cells (IC(50): 50-100 nM) exhibiting a KIT exon 11 internal tandem-duplication and in primary neoplastic MC harboring wild-type exon 11, whereas no effects were seen in MC exhibiting a polymorphism at amino acid 581 in exon 11.
  • INNO-406 was found to block KIT phosphorylation and expression in HMC-1.1 cells and C2 cells, but not in HMC-1.2 cells, whereas Lyn-phosphorylation was blocked by INNO-406 in all types of MC.
  • In human MC, the KIT D816V mutant introduces resistance, and in canine mastocytomas, an exon 11 polymorphism may be indicative of resistance against INNO-406.
  • [MeSH-major] Drug Resistance, Neoplasm. Mast Cells. Mastocytosis, Systemic. Mutation, Missense. Polymorphism, Genetic. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20685234.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 859212-16-1 / bafetinib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


77. Nechushtan H: The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol; 2010 May;42(5):551-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The complexity of the complicity of mast cells in cancer.
  • Mast cells are evolutionarly ancient cells of the immune cells which can secrete a variety of effector molecules.
  • Animal and pathologic studies suggest that mast cells may promote tumor growth in some cancer types but may act in an opposite manner in others.
  • In several mouse models a critical role of mast cells for tumor promotion was demonstrated.
  • In humans mast cells are dependent upon the tyrosine kinase receptor c-Kit.
  • These drugs probably ablate some tumor mast cells, in addition to their other known antitumor effects.
  • Understanding the complex roles of mast cells in cancer should aid in understanding mechanisms of current tyrosine kinase inhibitors, and the development of innovative anti-cancer therapies.
  • [MeSH-major] Mast Cells / enzymology. Mast Cells / physiology. Neoplasms / physiopathology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Disease Progression. Humans. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / physiopathology. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / physiopathology. Prognosis. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / physiology

  • MedlinePlus Health Information. consumer health - Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20026421.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 20
  •  go-up   go-down


78. Tan AS, Berridge MV: Differential effects of redox-cycling and arylating quinones on trans-plasma membrane electron transport. Biofactors; 2008;34(3):183-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For redox-cycling quinones, cell injury is associated with mitochondrial permeability transition, whereas arylating quinones directly depolarise the mitochondrial membrane and deplete ATP.
  • Here we investigate the effects of redox-cycling 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), arylating 1,4-benzoquinone (BQ) and mixed mechanism 2-methyl-1,4-naphthoquinone (MNQ) on PMET, viability and growth of P815 mouse mastocytoma cells.BQ and MNQ rapidly and extensively inhibited PMET as determined by WST-1 /mPMS reduction (IC50 3.5-5 microM at 30 min) whereas the effects of DMNQ were less pronounced.
  • In contrast, MTT reduction (cytosolic NADH dehydrogenase activity over 30 min) was weakly inhibited by BQ (IC50 20 microM) but not by MNQ or DMNQ and cell viability was unaffected.
  • Treatment with DMNQ, MNQ and to a lesser extent BQ inhibited cell proliferation as determined by MTT reduction at 48 h.
  • [MeSH-major] Cell Membrane / drug effects. Cell Membrane / metabolism. Electron Transport / drug effects. Quinones / pharmacology
  • [MeSH-minor] Animals. Benzoquinones / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Mice. Naphthoquinones / pharmacology. Oxidation-Reduction. Vitamin K 3 / pharmacology

  • Hazardous Substances Data Bank. 1,4-BENZOQUINONE .
  • Hazardous Substances Data Bank. MENADIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734119.001).
  • [ISSN] 1872-8081
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Naphthoquinones; 0 / Quinones; 3T006GV98U / benzoquinone; 6956-96-3 / 2,3-dimethoxy-1,4-naphthoquinone; 723JX6CXY5 / Vitamin K 3
  •  go-up   go-down


79. Reiter E, Azzi A, Zingg JM: Enhanced anti-proliferative effects of combinatorial treatment of delta-tocopherol and resveratrol in human HMC-1 cells. Biofactors; 2007;30(2):67-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced anti-proliferative effects of combinatorial treatment of delta-tocopherol and resveratrol in human HMC-1 cells.
  • Here we wanted to determine whether the combined treatment of mast cells with the two compounds inhibits cell proliferation more efficiently when compared to individual treatments.
  • Both compounds inhibit HMC-1 mastocytoma cell proliferation and reduce the activity of Protein Kinase B (PKB/Akt) by inhibiting its Ser473-phosphorylation.
  • The combination of 50 microM delta-tocopherol and 50 microM resveratrol inhibits proliferation of HMC-1 cells more efficiently when compared to single treatments.
  • Our data suggest that delta-tocopherol and resveratrol can act additively in reducing cell proliferation and PKB phosphorylation.
  • The combination of phytochemicals with relatively broad specificity on enzymes involved in signal transduction and gene expression may increase their activity in disease prevention by modulating several different molecular targets.
  • [MeSH-major] Cell Division / drug effects. Stilbenes / pharmacology. Tocopherols / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Drug Interactions. Enzyme Inhibitors / pharmacology. Humans. Mast Cells / drug effects. Mastocytoma. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. alpha-Tocopherol / pharmacology. beta-Tocopherol / pharmacology. gamma-Tocopherol / pharmacology

  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. VITAMIN E .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356579.001).
  • [ISSN] 0951-6433
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Stilbenes; 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; 9U6A490501 / beta-Tocopherol; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; H4N855PNZ1 / alpha-Tocopherol; JU84X1II0N / delta-tocopherol; Q369O8926L / resveratrol
  •  go-up   go-down


80. Liu Y, Furuta K, Teshima R, Shirata N, Sugimoto Y, Ichikawa A, Tanaka S: Critical role of protein kinase C betaII in activation of mast cells by monomeric IgE. J Biol Chem; 2005 Nov 25;280(47):38976-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical role of protein kinase C betaII in activation of mast cells by monomeric IgE.
  • Accumulating evidence suggests that IgE-mediated activation of mast cells occurs even in the absence of antigen, which is referred to as "monomeric IgE" responses.
  • Although monomeric IgE was found to induce a wide variety of responses, such as up-regulation of the FcepsilonRI, survival, cytokine production, histamine synthesis, and adhesion to fibronectin, it remains to be clarified how mast cells are activated in the absence of antigen.
  • Monomeric IgE-induced Ca(2+) influx was not observed in a mouse mastocytoma cell line, which lacks the expression of PKCbetaII, although Ca(2+) influx induced by cross-linking of the FcepsilonRI was intact.
  • Transfection of PKCbetaII cDNA was found to restore the Ca(2+) influx induced by monomeric IgE in this cell line.
  • Furthermore, the dominant negative form of PKCbetaII (PKCbetaII/T500V) significantly suppressed the Ca(2+) influx, histamine synthesis, and interleukin-6 production in another mouse mast cell line, which is highly sensitive to monomeric IgE.
  • [MeSH-major] Immunoglobulin E / metabolism. Mast Cells / enzymology. Mast Cells / immunology. Protein Kinase C / metabolism
  • [MeSH-minor] Animals. Base Sequence. Calcium Signaling. Cell Line. DNA, Complementary / genetics. Histamine / biosynthesis. Interleukin-6 / biosynthesis. Mice. Protein Kinase C beta. RNA Interference. Receptors, IgE / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Transfection

  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183638.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-6; 0 / Receptors, IgE; 0 / Recombinant Proteins; 37341-29-0 / Immunoglobulin E; 820484N8I3 / Histamine; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


81. Bai XF, Liu JQ, Joshi PS, Wang L, Yin L, Labanowska J, Heerema N, Zheng P, Liu Y: Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res; 2006 Aug 15;66(16):8241-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.
  • Tumor evasion of T-cell immunity remains a significant obstacle to adoptive T-cell therapy.
  • It is unknown whether the mode of immune evasion is dictated by the cancer cells or by the tumor antigens.
  • Taking advantage of the fact that multiple lineages of tumor cells share the tumor antigen P1A, we adoptively transferred transgenic T cells specific for P1A (P1CTL) into mice with established P1A-expressing tumors, including mastocytoma P815, plasmocytoma J558, and fibrosarcoma Meth A.
  • Although P1CTL conferred partial protection, tumors recurred in almost all mice.
  • Analysis of the status of the tumor antigen revealed that all J558 tumors underwent antigenic drift whereas all P815 tumors experienced antigenic loss.
  • Interestingly, although Meth A cells are capable of both antigenic loss and antigenic drift, the majority of recurrent Meth A tumors retained P1A antigen.
  • Our data showed that, in spite of their shared tumor antigen, different lineages of cancer cells use different mechanisms to evade T-cell therapy.
  • [MeSH-major] Antigens, Neoplasm / genetics. Immunotherapy, Adoptive / methods. Receptors, Antigen, T-Cell / genetics. T-Lymphocytes / immunology. T-Lymphocytes / transplantation
  • [MeSH-minor] Animals. Apoptosis. Cell Division. Cell Survival. DNA Primers. Humans. Mice. Mice, Inbred BALB C. Mice, Transgenic. Polymerase Chain Reaction. Spleen / transplantation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912204.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA58033; United States / NCI NIH HHS / CA / R21CA116678
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA Primers; 0 / Receptors, Antigen, T-Cell; 0 / tumor rejection antigen P815A, mouse
  •  go-up   go-down


82. Xu P, Okkeri J, Hanisch S, Hu RY, Xu Q, Pomorski TG, Ding XY: Identification of a novel mouse P4-ATPase family member highly expressed during spermatogenesis. J Cell Sci; 2009 Aug 15;122(Pt 16):2866-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel mouse P4-ATPase family member highly expressed during spermatogenesis.
  • In mouse testis, FetA protein is detected in gamete cells, from pachytene spermatocytes to mature sperms, and its intracellular localization is tightly related with acrosome formation, a process that involves intensive intracellular vesicle formation and fusion.
  • Furthermore, loss-of-function of FetA by RNA interference in mastocytoma P815 cells profoundly perturbs the structural organization of the Golgi complex and causes loss of constitutive secretion at lower temperature.
  • Our findings point to an essential role of FetA in Golgi morphology and secretory function, suggesting a crucial role for this novel murine P4-ATPase in spermatogenesis.
  • [MeSH-minor] Amino Acid Sequence. Animals. Biological Transport. Cell Line, Tumor. Endocytosis. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Developmental. Golgi Apparatus / enzymology. Golgi Apparatus / pathology. Golgi Apparatus / ultrastructure. Lipid Metabolism. Male. Mastocytoma / enzymology. Mastocytoma / pathology. Mice. Molecular Sequence Data. Organ Specificity. Phylogeny. RNA, Messenger / genetics. RNA, Messenger / metabolism. Saccharomyces cerevisiae / metabolism. Sequence Alignment. Testis / cytology. Testis / embryology. Testis / enzymology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657017.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF377342
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.6.1.- / Adenosine Triphosphatases
  •  go-up   go-down


83. Sundram UN, Natkunam Y: Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. J Cutan Pathol; 2007 Apr;34(4):289-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis.
  • BACKGROUND: Cutaneous mast cell disorders are uncommon, but a subset, especially mastocytoma and mast cell leukemia, can histologically mimic myeloid leukemia cutis.
  • METHODS: We stained 17 cases of cutaneous mast cell disease and 20 cases of myeloid leukemia cutis with Giemsa, toluidine blue, or pinacyanol erythrosinate (PE), as well as with antibodies against mast cell tryptase, microphthalmia transcription factor (MiTF), CD117 (c-kit), myeloperoxidase, CD43, CD25, CD2, and CD68.
  • RESULTS: Mast cell tryptase and MiTF emerged as highly sensitive and specific markers for mast cell disease in this context, as both antibodies stained all cases of mast cell diseases but none of myeloid leukemia cutis.
  • Although CD117 stained all cases of mast cell disease, it also stained 2 of 18 cases of myeloid leukemia cutis.
  • PE appeared to be specific for mast cell disease, as 11 of 12 cases stained with this marker, compared with 0 of 18 cases of myeloid leukemia cutis.
  • CONCLUSIONS: Our results show that mast cell tryptase and MiTF are equally effective in distinguishing mast cell disease from myeloid leukemia cutis.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Mast Cells / pathology. Mastocytosis, Cutaneous / diagnosis. Microphthalmia-Associated Transcription Factor / metabolism. Tryptases / metabolism
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, CD2 / metabolism. Antigens, CD43 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Interleukin-2 Receptor alpha Subunit / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Leukemia, mast-cell.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Microphthalmia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381798.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD2; 0 / Antigens, CD43; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Microphthalmia-Associated Transcription Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


84. Nishikawa H, Wakano K, Kitani S: Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell. Biochem Biophys Res Commun; 2007 Oct 19;362(2):504-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell.
  • We studied the effect of catechins, mainly EGCG, on the activation of mast cell line canine cutaneous mastocytoma cells (CM-MC).
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Cells, Cultured. Cytosol / drug effects. Cytosol / metabolism. Dose-Response Relationship, Drug. Humans. Mast Cells / drug effects. Mast Cells / enzymology. Mast Cells / metabolism. Neutrophils / cytology. Neutrophils / drug effects. Neutrophils / metabolism. Onium Compounds / pharmacology. Phosphoproteins / metabolism. Protease Inhibitors / pharmacology. Protein Subunits / metabolism. Protein Transport / drug effects. Reactive Oxygen Species / metabolism. Time Factors. beta-N-Acetylhexosaminidases / secretion. p-Methoxy-N-methylphenethylamine / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707774.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Onium Compounds; 0 / Phosphoproteins; 0 / Protease Inhibitors; 0 / Protein Subunits; 0 / Reactive Oxygen Species; 0 / Tea; 0 / neutrophil cytosol factor 40K; 0 / neutrophil cytosol factor 67K; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 6HJ411TU98 / diphenyleneiodonium; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 1.6.3.1 / NADPH Oxidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


85. Gück T, Fuhrmann H: [Pathobiochemical importance of phospholipases for the release of mast cell mediators]. Dtsch Tierarztl Wochenschr; 2005 Nov;112(11):404-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathobiochemical importance of phospholipases for the release of mast cell mediators].
  • We investigated the influence of polyunsaturated fatty acids on the activity of the cytosolic phospholipase A2 (cPLA2) in the canine mastocytoma cell line C2 as a model for canine atopic dermatitis (CAD).
  • Cells were cultured in a basic medium or in media supplemented with different fatty acids (14 microM) for eight days.
  • Furthermore in these cells and in C2 cultured in 22:6n3 supplemented medium decreased the cPLA2 activity after stimulation.
  • [MeSH-major] Dermatitis, Atopic / veterinary. Dog Diseases / pathology. Fatty Acids, Unsaturated / pharmacology. Inflammation Mediators / metabolism. Mast Cells / metabolism. Phospholipases / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Dogs. Mastocytoma / pathology. Mastocytoma / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366033.001).
  • [ISSN] 0341-6593
  • [Journal-full-title] DTW. Deutsche tierärztliche Wochenschrift
  • [ISO-abbreviation] DTW. Dtsch. Tierarztl. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Unsaturated; 0 / Inflammation Mediators; EC 3.1.- / Phospholipases
  •  go-up   go-down


86. Montgomery KW, van der Woerdt A, Aquino SM, Sapienza JS, Ledbetter EC: Periocular cutaneous mast cell tumors in cats: evaluation of surgical excision (33 cases). Vet Ophthalmol; 2010 Jan;13(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periocular cutaneous mast cell tumors in cats: evaluation of surgical excision (33 cases).
  • OBJECTIVE: To describe feline periocular cutaneous mast cell tumor (CMCT) clinical features, rates of local tumor recurrence and metastases, and cat survival time following surgical excision.
  • PROCEDURES: Medical records of cats diagnosed with periocular CMCTs were reviewed; cats were included if CMCTs were surgically excised and the diagnosis confirmed by histopathology.
  • Local tumor control was achieved in 22/23 cats with a minimum follow-up of 30 days (median follow-up time of 711 days); one cat developed disseminated CMCTs but no local recurrence.
  • Metastatic disease involving peripheral lymph nodes or abdominal viscera was not detected in any cat at any time during the study.
  • [MeSH-minor] Animals. Cats. Female. Male. Mast Cells / pathology. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149172.001).
  • [ISSN] 1463-5224
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Welker P, Wanner R, Zuberbier T, Groneberg DA, Henz BM: Gene expression and regulation of transcription factor activator protein-2 alpha in human mast cells. Allergy; 2005 Aug;60(8):1046-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression and regulation of transcription factor activator protein-2 alpha in human mast cells.
  • BACKGROUND: The transcription factor activator protein (AP)-2 regulates cell-type specific gene expression during development and differentiation, but its role in mast cell development has so far not been explored.
  • METHODS: Gene expression and regulation of AP2 was assessed in normal skin, diseases with increased mast cell numbers, and in vitro models of mast cell differentiation.
  • RESULTS: AP-2alpha-protein was not detectable in normal skin but in mastocytoma lesional mast cells.
  • AP-2alpha-mRNA and -protein were also detected in leukemic mast cells (HMC-1), in the adherent fraction of peripheral blood (PBMC) and umbilical cord blood mononuclear cells (CBMC), and AP-2alpha-mRNA at low levels in isolated-purified mast cells.
  • During culture with fibroblast supernatants or SCF, AP-2alpha-mRNA was de novo expressed in KU812-cells, maintained at about the same level in PBMC and CBMC, and upregulated in HMC-1-cells.
  • In contrast, tryptase expression increased in all cells throughout culture, as did c-Kit in normal cells, whereas in both leukemic cell lines, c-Kit was maintained unchanged at about the same level.
  • CONCLUSIONS: These findings suggest a continuous activation of AP-2alpha in mastocytomas and mast cell leukemia and its transient upregulation during c-Kit dependent early steps of normal mast cell differentiation.
  • [MeSH-major] Gene Expression. Gene Expression Regulation. Mast Cells / metabolism
  • [MeSH-minor] Cell Aging / physiology. Cell Line. Fluorescent Antibody Technique. Humans. Immunohistochemistry. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Serine Endopeptidases / metabolism. Skin / metabolism. Stem Cells / metabolism. Tryptases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969686.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


88. Harris AL, Ryan JJ, Farrell N: Biological consequences of trinuclear platinum complexes: comparison of [[trans-PtCl(NH3)2]2mu-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with its noncovalent congeners. Mol Pharmacol; 2006 Feb;69(2):666-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All compounds induce caspase-dependent apoptosis in both primary mast cells and transformed mastocytomas, although with a smaller IC(50) value in the transformed cells.
  • In cells deficient in either the tumor suppressor proteins p53 or Bax, apoptosis was least affected in the case of II, but in all cases the effect of p53 deficiency was greater than that of Bax.
  • Cellular accumulation was enhanced in mastocytomas over primary mast cells, suggesting a mechanism for enhancement of tumor cell selectivity.
  • [MeSH-minor] Animals. Apoptosis. Caspases / metabolism. Enzyme Activation. Mast Cells / drug effects. Mast Cells / enzymology. Mice. Mice, Inbred C57BL. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275707.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 1R01-AI43433; United States / NCI NIH HHS / CA / 1R01-CA91839; United States / NCI NIH HHS / CA / CA78754
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BBR 3464; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 3.4.22.- / Caspases
  •  go-up   go-down


89. Horiyama S, Honda C, Suwa K, Umemoto Y, Okada Y, Semma M, Ichikawa A, Takayama M: Sensitive and simple analysis of sorbic acid using liquid chromatography with electrospray ionization tandem mass spectrometry. Chem Pharm Bull (Tokyo); 2008 Apr;56(4):578-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it is still unclear whether SA and its salts are actually incorporated in these organisms and a higher organisms like mammalian cells.
  • We also show that the method is useful to analyze SA level in the cytosol of mastocytoma cells, which were pretreated with SA.
  • These results suggest the applicability of this method for the highly sensitive determination of SA in the mammalian tissues and cells.
  • [MeSH-minor] Acetates. Cell Differentiation. Cell Line, Tumor. Chromatography, Liquid. Cytosol / chemistry. Humans. Reproducibility of Results. Solvents. Spectrometry, Mass, Electrospray Ionization

  • Hazardous Substances Data Bank. SORBIC ACID .
  • Hazardous Substances Data Bank. AMMONIUM ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379111.001).
  • [ISSN] 0009-2363
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Acetates; 0 / Food Preservatives; 0 / Solvents; RRE756S6Q2 / ammonium acetate; X045WJ989B / Sorbic Acid
  •  go-up   go-down


90. Bouabdallah I, M'Barek LA, Zyad A, Ramdani A, Zidane I, Melhaoui A: Anticancer effect of three pyrazole derivatives. Nat Prod Res; 2006 Sep;20(11):1024-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation of the cytotoxic properties in vitro of three synthetic tripods containing pyrazole: N,N-bis[(3,5-dimethylpyrazol-1-yl)methyl]aniline (1); N,N-tetrakis[(3,5-dimethylpyrazol-1-yl)methyl]-para-phenylenediamine (2); and N,N-tetrakis-[(1,5-dimethylpyrazol-3-yl)methyl]-para-phenylenediamine (3), was examined for their cytotoxic activity on two tumor cell lines: P815 (murin mastocytoma) and Hep (human laryngeal carcinome).
  • While the compound 2 shows a small cytotoxic activity, compounds 1 and 3 are more cytotoxic against both cell lines.
  • However, this cytotoxicity is more pronounced against Hep cell line (IC50: 3.25 microg mL(-1) for compound 1 and 6.92 microg mL(-1) for compound 3) than P815 cell line (IC50: 17.82 microg mL(-1) for compound 1 and 37.21 microg mL(-1) for compound 3).
  • Interestingly, the cytotoxicity induced by compound 1 against Hep cell line is more important than that induced by adriamycin used as a positive control.
  • [MeSH-minor] Cell Line, Tumor. Humans. Molecular Structure

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050185.001).
  • [ISSN] 1478-6419
  • [Journal-full-title] Natural product research
  • [ISO-abbreviation] Nat. Prod. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / N,N-bis((3,5-dimethylpyrazol-1-yl)methyl)aniline; 0 / N,N-tetrakis((3,5-dimethylpyrazol-1-yl)methyl)-para-phenylenediamine; 0 / Phenylenediamines; 0 / Pyrazoles
  •  go-up   go-down


91. Shi G, Mao J, Yu G, Zhang J, Wu J: Tumor vaccine based on cell surface expression of DcR3/TR6. J Immunol; 2005 Apr 15;174(8):4727-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor vaccine based on cell surface expression of DcR3/TR6.
  • Solid-phase TR6 can trigger reverse signaling of LIGHT and FasL expressed on T cells, and lead to T cell costimulation.
  • In this study, we engineered tumor cells to express cell surface TR6 and used these cells as a tumor vaccine.
  • We demonstrated that mastocytoma P815 cells expressing surface TR6 (TR6-P815) effectively augmented the T cells response in vitro and ex vivo in terms of proliferation, as well as IL-2 and IFN-gamma secretion.
  • TR6-P815 cells had reduced tumorigenicity compared with parental P815 cells.
  • When inactivated TR6-P815 cells were employed as a vaccine, they protected the mice from challenge with live parental P815 cells, and eliminated established P815 tumors.
  • The cell surface TR6-based tumor vaccine was also effective against low antigenicity tumors, such as B16 melanoma; co-administration of bacillus Calmette-Guérin further enhanced the vaccine's efficacy.
  • Thus, cell surface TR6 expression is a useful addition to our tumor vaccine arsenal.
  • [MeSH-major] Cancer Vaccines / isolation & purification. Membrane Glycoproteins / immunology. Receptors, Cell Surface / immunology. Receptors, Tumor Necrosis Factor / immunology
  • [MeSH-minor] Animals. Antigens, Neoplasm. Cell Line, Tumor. Cell Membrane / immunology. Female. Humans. Immunologic Factors / administration & dosage. In Vitro Techniques. Lymphocyte Activation. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Knockout. Mice, Nude. Neoplasms, Experimental / immunology. Neoplasms, Experimental / therapy. Receptors, Tumor Necrosis Factor, Member 6b. T-Lymphocytes / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814697.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Immunologic Factors; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


92. Olver S, Apte S, Baz A, Kienzle N: The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens; 2007 Apr;69(4):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?
  • Successful tumour immunity relies on innate and adaptive immune responses, with cytokines like interleukin 4 (IL-4) known to influence tumour clearance in both positive and negative ways.
  • Here, we summarise some of the murine tumour models used over the past two decades to assess the impact of IL-4 on tumour immunity, with emphasis on the effects of IL-4 on the tumour-induced CD8 T-cell response.
  • These data are compared with our own recent studies showing that IL-4 impairs CD8+ T-cell-mediated immunity against the mastocytoma cell line P815 expressing the immunogenic HLA-CW3 gene; moreover, we hypothesise that quantitative and qualitative differences in the HLA-CW3-induced CD8+ T-cell response impair control of tumour growth and aid the development of secondary tumours.
  • We conclude that the duplicitous effects of IL-4 on tumour immunity depend on the type of effector cell (adaptive/innate) mediating tumour clearance and whether tumour growth depends on stromal infrastructure.
  • Thus, the search for factors that improve or weaken the effectiveness of tumour-specific T cells has to be continued to improve modern approaches of immunotherapy against cancer.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389011.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / HLA-C Antigens; 207137-56-2 / Interleukin-4
  • [Number-of-references] 44
  •  go-up   go-down


93. Mahadevan B, Luch A, Bravo CF, Atkin J, Steppan LB, Pereira C, Kerkvliet NI, Baird WM: Dibenzo[a,l]pyrene induced DNA adduct formation in lung tissue in vivo. Cancer Lett; 2005 Sep 8;227(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, dibenzo[a,l]pyrene (DBP) has been found to be the strongest tumor-initiating PAH ever tested in rodent skin and mammary tumor models.
  • Toxicity of DBP was revealed by a decrease in body and organ weight of mice while no apparent cell death was observed on P815 mastocytoma cells (allograft model) in vitro.
  • However, treatment of P815 cells in vitro with the ultimate carcinogenic metabolite of DBP, the fjord region (-)-anti-11,12-diol 13,14-epoxide [(-)-anti-DBPDE], resulted in the total loss of cell viability.
  • The data from this in vivo model are consistent with previous metabolic activation results obtained with DBP in human cells in culture.
  • [MeSH-minor] Animals. Cell Line. Cell Survival / drug effects. DNA Damage. Female. Mice. Mice, Inbred C57BL. Mice, Inbred DBA

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIBENZO(A,L)PYRENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051029.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 28825; United States / NIEHS NIH HHS / ES / P30ES00210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzopyrenes; 0 / DNA Adducts; 191-30-0 / dibenzo(a,l)pyrene
  •  go-up   go-down


94. Purnell B, Sato A, O'kelley A, Price C, Summerville K, Hudson S, O'hare C, Kiakos K, Asao T, Lee M, Hartley JA: DNA interstrand crosslinking agents: synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD). Bioorg Med Chem Lett; 2006 Nov 1;16(21):5677-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 11 and 12 demonstrated enhanced cytotoxicity over the monomer counterparts against the growth of P815 murine mastocytoma cells in culture.
  • Both compounds were found to induce apoptosis in P815 cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPROPANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919946.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Cyclopropanes; 0 / Indoles; 0 / Pyrroles; 0 / pyrrolo(2,1-c)(1,4)benzodiazepine; 12794-10-4 / Benzodiazepines; 496-15-1 / indoline; 9007-49-2 / DNA; 99TB643425 / cyclopropane
  •  go-up   go-down


95. Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P: Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol; 2007 Oct;35(10):1510-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
  • Aggressive mast cell (MC) tumors are hematopoietic neoplasms characterized by uncontrolled growth of MC and resistance to conventional drugs.
  • In most cases, the tyrosine kinase (TK) receptor KIT is involved in malignant cell growth.
  • We examined the effects of four TK inhibitors (imatinib, midostaurin, nilotinib, and dasatinib) on C2 canine mastocytoma cells, as well as primary neoplastic canine MC.
  • As assessed by (3)H-thymidine incorporation experiments, all TK inhibitors produced dose-dependent inhibition of proliferation in C2 cells with the following IC(50) values: imatinib: 269 +/- 180 nM, midostaurin: 157 +/- 35 nM, nilotinib: 55 +/- 24 nM, dasatinib: 12 +/- 3 nM.
  • Growth-inhibitory effects of TK inhibitors were also observed in primary neoplastic mast cells, although IC(50) values for each drug varied from patient to patient, with midostaurin being the most potent agent in all samples tested.
  • In consecutive experiments, we were able to show that TK inhibitors cooperate with each other in producing growth inhibition in C2 cells with synergistic effects observed with most drug combinations.
  • In flow cytometry and TUNEL assay experiments, growth-inhibitory effects of TK inhibitors were found to be associated with cell-cycle arrest and apoptosis.
  • Together, these data show that several TK-targeting drugs induce apoptosis and inhibit proliferation in canine mastocytoma cells in vitro, and that synergistic drug interactions can be obtained.
  • Clinical trials are now warranted to explore whether these TK inhibitors also counteract growth of neoplastic cells in vivo in patients with aggressive MC tumors.
  • [MeSH-major] Dog Diseases / drug therapy. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / veterinary. Mast-Cell Sarcoma / drug therapy. Mast-Cell Sarcoma / veterinary. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Dogs. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Mast Cells / metabolism. Mast Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681669.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


96. Zhang XQ, Mei WH, Qian GX: [Activity analysis of human beta β2-microglobulin gene promoter in P815 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Nov;21(6):672-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Activity analysis of human beta β2-microglobulin gene promoter in P815 cells].
  • AIM: To clone the human beta2-microglobulin(beta2m) gene promoter and study its activity in P815 cells.
  • A mouse mastocytoma cell line P815 was transiently and stably transfected with the plasmid containing human beta2m gene promoter and enhanced green fluorescence protein(EGFP) gene.
  • The mRNA expression of EGFP in transiently transfected cells was quantified by RT-PCR and that in stably transfected cells was detected by fluorescence microscope and flow cytometry(FCM).
  • There was no difference in the fluorescence positive cell rate between the IFN-gamma-treated group and the control group.
  • CONCLUSION: Human beta2m gene promoter is active in mouse mastocytoma P815 cells.
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Flow Cytometry. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Interferon-gamma / pharmacology. Mastocytoma / metabolism. Mice. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Nucleic Acid. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256022.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / beta 2-Microglobulin; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


97. Cole R, Chesen AB, Pool R, Watkins J: Imaging diagnosis--equine mast cell tumor. Vet Radiol Ultrasound; 2007 Jan-Feb;48(1):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis--equine mast cell tumor.
  • Equine mast cell tumors are typically benign solitary growths of the head, neck, trunk, or limbs.
  • In this report, we describe the diagnosis, clinical features, and management of mast cell tumors in the rear limb of a horse.
  • [MeSH-major] Horse Diseases / radiography. Mast-Cell Sarcoma / veterinary. Soft Tissue Neoplasms / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Hindlimb / radiography. Horses. Lameness, Animal / etiology. Lameness, Animal / radiography. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236357.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med; 2007 Oct;13(10):1211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.
  • Myc is a pleiotropic transcription factor that is overexpressed in many human cancers and instructs many extracellular aspects of the tumor tissue phenotype, including remodeling of tumor stroma and angiogenesis.
  • Here we show in a beta-cell tumor model that activation of Myc in vivo triggers rapid recruitment of mast cells to the tumor site-a recruitment that is absolutely required for macroscopic tumor expansion.
  • In addition, treatment of established beta-cell tumors with a mast cell inhibitor rapidly triggers hypoxia and cell death of tumor and endothelial cells.
  • Inhibitors of mast cell function may therefore prove therapeutically useful in restraining expansion and survival of pancreatic and other cancers.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Mast Cells / metabolism. Neovascularization, Pathologic / etiology. Pancreatic Neoplasms / blood supply. Proto-Oncogene Proteins c-myc / physiology
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Cells, Cultured. Chemokine CCL2 / metabolism. Chemokine CCL5 / metabolism. Femur / cytology. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Mice. Mice, Inbred C57BL. Mice, Transgenic. Oligonucleotide Array Sequence Analysis


99. Turrel JM, Farrelly J, Page RL, McEntee MC: Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002). J Am Vet Med Assoc; 2006 Mar 15;228(6):898-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002).
  • OBJECTIVE: To determine the efficacy of strontium 90 beta irradiation in the management of cutaneous mast cell tumors (CMCTs) in cats.
  • PROCEDURE: Medical records of cats with CMCTs in which tumors were radiated by use of a strontium 90 ophthalmic applicator from 1992 to 2002 were reviewed.
  • Cats were included if CMCT was diagnosed, there were no other sites of MCT involvement at the time of treatment, and records contained adequate follow-up information to permit retrospective assessment of local tumor control.
  • RESULTS: 54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 beta irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that strontium 90 beta irradiation resulted in long-term tumor control and should be considered an effective alternative to surgical resection in management of CMCTs in cats.
  • [MeSH-major] Cat Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary. Strontium Radioisotopes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536702.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Strontium Radioisotopes
  •  go-up   go-down


100. Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E: Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med; 2008 Jul-Aug;22(4):1001-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
  • BACKGROUND: Mast cell tumors (MCTs) with bone marrow (BM) involvement are poorly documented in dogs and are associated with a poor prognosis.
  • Imatinib was administered if tumor-associated tyrosine kinase KIT was aberrant.
  • BM infiltration with mast cells (MCs) was observed in all dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564225.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement